[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 750
1. Gerstner ER, Abrey LE, Schiff D, Ferreri AJ, Lister A, Montoto S, Tsang R, Thiel E, Graus F, Behringer D, Illerhaus G, Weaver S, Wen P, Voloschin A, Harris NL, Batchelor TT: CNS Hodgkin lymphoma. Blood; 2008 Sep 1;112(5):1658-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS Hodgkin lymphoma.
  • Central nervous system (CNS) involvement by Hodgkin lymphoma (HL) is rare.
  • Detailed information was collected on 16 patients, the largest number to date, with meningeal or parenchymal CNS-HL confirmed by histopathology (15) or CSF (1).
  • Eight patients presented with CNS-HL at diagnosis, 2 of whom had isolated CNS disease, while 8 patients developed CNS-HL at relapse.
  • Median overall survival for all 16 patients was 60.9 months from first diagnosis of HL (systemic or CNS) and 43.8 months from diagnosis of CNS-HL.
  • Although a majority of patients have died, long-term survival is possible in patients who achieve a complete response to treatment, particularly those who present with CNS involvement or involvement of the CNS is the sole site of relapsed disease.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Hodgkin Disease / therapy
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Female. Humans. Male. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / pathology. Meningeal Neoplasms / therapy. Middle Aged. Prognosis. Recurrence. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Mar;82(5):1117-21 [10737396.001]
  • [Cites] Acta Neuropathol. 2000 Jun;99(6):709-14 [10867808.001]
  • [Cites] Radiat Med. 2000 May-Jun;18(3):205-8 [10972552.001]
  • [Cites] Brain Pathol. 2001 Jul;11(3):387-8; 393 [11414479.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1667-71 [15370222.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3182 [17634503.001]
  • [Cites] Cancer. 1979 Apr;43(4):1497-506 [376094.001]
  • [Cites] Cancer. 1983 Oct 1;52(7):1301-7 [6883291.001]
  • [Cites] Clin Lab Haematol. 1989;11(4):331-8 [2605874.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1437-8 [17416864.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4228-30 [15483035.001]
  • (PMID = 18591379.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R13 CA124293
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3710443
  •  go-up   go-down


2. Bäcklund LM, Grandér D, Brandt L, Hall P, Ekbom A: Parathyroid adenoma and primary CNS tumors. Int J Cancer; 2005 Mar 1;113(6):866-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parathyroid adenoma and primary CNS tumors.
  • There are several case reports of MEN Type 1-associated central nervous system (CNS) tumors.
  • To determine if there is an association between parathyroid adenomas and CNS tumors, we used Swedish registry data to identify all individuals operated on for parathyroid adenomas between 1958-99 (n = 12,468).
  • Follow-up for the occurrence of CNS tumors in these individuals was through linkage with the Swedish Cancer Registry.
  • There were 70 observed cases of a CNS tumor diagnosed after a parathyroid adenoma, to be compared to 35 expected (standard incidence ratio [SIR] = 2.0; 95% confidence interval [CI] = 1.5-2.5).
  • These results strongly indicate an association between these tumor forms that may be genetic, environmental (such as radiation) or a combination of both.
  • [MeSH-major] Adenoma / epidemiology. Central Nervous System Neoplasms / epidemiology. Parathyroid Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Neoplasms, Second Primary / epidemiology. Registries. Retrospective Studies. Sweden / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15515018.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Tatsumi M, Miller JH, Wahl RL: 18F-FDG PET/CT in evaluating non-CNS pediatric malignancies. J Nucl Med; 2007 Dec;48(12):1923-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET/CT in evaluating non-CNS pediatric malignancies.
  • We reviewed our experience of (18)F-FDG PET/CT in noncentral nervous system (CNS) pediatric malignancies and evaluated if PET/CT provided additional information to conventional imaging (CI) examinations to determine the efficacy of this new imaging modality in the clinical setting.
  • METHODS: One-hundred fifty-one consecutive FDG PET/CT examinations in 55 pediatric patients with non-CNS malignant tumors were reviewed.
  • PET/CT was demonstrated to be an accurate imaging modality in evaluating pediatric patients with non-CNS malignancies.
  • [MeSH-major] Fluorodeoxyglucose F18. Neoplasms / radiography. Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Magnetic Resonance Imaging. Male. Retrospective Studies


Advertisement
4. Engelhard HH, Corsten LA: Leptomeningeal metastasis of primary central nervous system (CNS) neoplasms. Cancer Treat Res; 2005;125:71-85
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal metastasis of primary central nervous system (CNS) neoplasms.
  • Leptomeningeal dissemination of primary CNS tumors varies widely by histologic subtype.
  • In certain tumors including medulloblastoma, ependymoma, germ cell tumors, and primary CNS lymphoma, seeding of the cerebrospinal fluid space is a critical factor in determining stage, prognosis and appropriate therapy.
  • Other tumor types, such as glioma, may have radiographic evidence of leptomeningeal metastases without clear impact on prognosis or therapy.
  • [MeSH-major] Brain Neoplasms / pathology. Central Nervous System Neoplasms / pathology. Meningeal Neoplasms / secondary
  • [MeSH-minor] Adult. Child. Humans. Incidence

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211884.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 86
  •  go-up   go-down


5. Wernicke AG, Sherr DL, Schwartz TH, Pannullo SC, Stieg PE, Boockvar JA, Ivanidze J, Moliterno JA, Parashar B, Trichter S, Sabbas AM, Nori D: Feasibility and safety of GliaSite brachytherapy in treatment of CNS tumors following neurosurgical resection. J Cancer Res Ther; 2010 Jan-Mar;6(1):65-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility and safety of GliaSite brachytherapy in treatment of CNS tumors following neurosurgical resection.
  • PURPOSE: To investigate feasibility and safety of GliaSite brachytherapy for treatment of central nervous system (CNS) tumors following neurosurgical resection.
  • MATERIALS AND METHODS: In the period from 2004 to 2007, 10 consecutive adult patients with recurrent, newly diagnosed, and metastatic brain malignancies underwent GliaSite brachytherapy following maximally safe neurosurgical resection.
  • [MeSH-major] Brachytherapy / methods. Brain Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Feasibility Studies. Female. Humans. Male. Middle Aged. Neurosurgical Procedures. Pilot Projects. Radiotherapy Dosage. Radiotherapy, Adjuvant / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479550.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] India
  •  go-up   go-down


6. Crawford JR, Santi MR, Cornelison R, Sallinen SL, Haapasalo H, MacDonald TJ: Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors. J Neurooncol; 2009 Oct;95(1):49-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors.
  • The purpose is to determine the incidence of active and latent human herpesvirus-6 (HHV-6) infection in a large cohort of adult primary and recurrent CNS tumors.
  • We screened a tissue microarray (TMA) containing more than 200 adult primary and recurrent CNS tumors with known clinical information for the presence of HHV-6 DNA by in situ hybridization (ISH) and protein by immunohistochemistry (IHC).
  • One hundred six of 224 (47%) CNS tumors were positive for HHV-6 U57 Major Capsid Protein (MCP) gene by ISH compared to 0/25 non tumor control brain (P = 0.001).
  • Fourteen of 30 (47%) tumors were HHV-6 MCP positive by nested PCR compared to 0/25 non-tumor brain controls (P = 0.001), revealing HHV-6 Variant A in 6 of 14 samples.
  • HHV-6A/B early (p41) and late (gp116/64/54) antigens were detected by IHC in 66 of 277 (24%) (P = 0.003) and 84 of 282 (35%) (P = 0.002) tumors, respectively, suggesting active infection.
  • Glial tumors were 3 times more positive by IHC compared to non glial tumors for both HHV-6 gp116/64/54 (P = 0.0002) and HHV-6 p41 (P = 0.004).
  • HHV-6 early and late antigens are detected in adult primary and recurrent CNS tumors more frequently in glial tumors.
  • We hypothesize that the glial-tropic features of HHV-6 may play an important modifying role in tumor biology that warrants further investigation.
  • [MeSH-major] Antigens, Viral. Central Nervous System Neoplasms / genetics. Central Nervous System Neoplasms / virology. Glioma / genetics. Glioma / virology. Herpesvirus 6, Human / isolation & purification
  • [MeSH-minor] Adult. Antigens, CD / metabolism. CD48 Antigen. Capsid Proteins / genetics. Capsid Proteins / metabolism. Humans. Survival Analysis. Viral Envelope Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19424665.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K12NS052159-01A
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Viral; 0 / CD48 Antigen; 0 / Capsid Proteins; 0 / Viral Envelope Proteins
  •  go-up   go-down


7. Armstrong GT, Jain N, Liu W, Merchant TE, Stovall M, Srivastava DK, Gurney JG, Packer RJ, Robison LL, Krull KR: Region-specific radiotherapy and neuropsychological outcomes in adult survivors of childhood CNS malignancies. Neuro Oncol; 2010 Nov;12(11):1173-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Region-specific radiotherapy and neuropsychological outcomes in adult survivors of childhood CNS malignancies.
  • Childhood cancer survivors exposed to CNS irradiation are at increased risk for neurocognitive deficits; however, limited data exist linking outcomes with region-specific exposure to CNS irradiation.
  • We report associations between region-specific radiation dose and self-reported neurocognitive and health-related quality of life (HRQOL) outcomes in 818 adult survivors of childhood central nervous system (CNS) malignancies from the Childhood Cancer Survivor Study.
  • Adult survivors of childhood CNS malignancies report higher rates of neuropsychological and HRQOL outcomes, which vary as a function of dose to specific neuroanatomical regions.

  • MedlinePlus Health Information. consumer health - Memory.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Geriatr Soc. 2009 Apr;57(4):594-603 [19220558.001]
  • [Cites] Neurologist. 2009 Mar;15(2):71-9 [19276784.001]
  • [Cites] J Natl Cancer Inst. 2009 Jul 1;101(13):946-58 [19535780.001]
  • [Cites] Psychooncology. 2009 Jul;18(7):762-6 [19061197.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3691-7 [19581535.001]
  • [Cites] Epilepsia. 2009 Jun;50(6):1547-59 [19175397.001]
  • [Cites] Neuropsychology. 2009 Nov;23(6):705-17 [19899829.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1002-8 [19783376.001]
  • [Cites] Neurology. 2001 Jun 12;56(11):1539-45 [11402112.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3470-6 [11481352.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] Support Care Cancer. 2002 Nov;10(8):579-600 [12436217.001]
  • [Cites] Psychooncology. 2003 Apr-May;12(3):213-25 [12673806.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3255-61 [12947060.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):999-1006 [15020603.001]
  • [Cites] Med Pediatr Oncol. 1990;18(4):304-10 [2355890.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1348-56 [2072138.001]
  • [Cites] Med Care. 1992 Jun;30(6):473-83 [1593914.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Feb 15;31(4):983-98 [7860415.001]
  • [Cites] J Neurooncol. 1996 Jul;29(1):91-101 [8817420.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1723-8 [9586884.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1546-54 [16115736.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):396-402 [16353203.001]
  • [Cites] J Neurosurg. 2006 Feb;104(2 Suppl):94-102 [16506496.001]
  • [Cites] J Pediatr Psychol. 2006 Apr;31(3):272-80 [15788715.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):210-21 [16472938.001]
  • [Cites] Support Care Cancer. 2006 Jul;14(7):779-82 [16482447.001]
  • [Cites] Radiat Res. 2006 Jul;166(1 Pt 2):141-57 [16808603.001]
  • [Cites] J Pediatr Psychol. 2007 Oct;32(9):1040-9 [17329318.001]
  • [Cites] Arch Phys Med Rehabil. 2008 Jan;89(1):128-36 [18164342.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):435-46 [18268128.001]
  • [Cites] J Neuroradiol. 2008 Mar;35(1):42-50 [18206240.001]
  • [Cites] Pediatr Blood Cancer. 2008 Aug;51(2):275-9 [18421716.001]
  • [Cites] Neuroimage. 2008 Aug 15;42(2):1032-44 [18602840.001]
  • [Cites] Epilepsia. 2008 Aug;49(8):1470-4 [18479383.001]
  • [Cites] J Int Neuropsychol Soc. 2008 Sep;14(5):883-9 [18764984.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2188-97 [18792068.001]
  • [Cites] J Int Neuropsychol Soc. 2009 Jan;15(1):31-41 [19128526.001]
  • [Cites] J Clin Oncol. 2009 May 10;27(14):2308-18 [19364948.001]
  • (PMID = 20716593.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / U24-CA55727
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3098024
  •  go-up   go-down


8. Offiah CE, Turnbull IW: The imaging appearances of intracranial CNS infections in adult HIV and AIDS patients. Clin Radiol; 2006 May;61(5):393-401
MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The imaging appearances of intracranial CNS infections in adult HIV and AIDS patients.
  • The spectrum of pathology affecting the central nervous system (CNS) in patients suffering from acquired immunodeficiency syndrome (AIDS) is broad and comprises predominantly opportunistic infections and neoplasms.
  • Attention will be paid specifically to those CNS manifestations occurring in the adult HIV and AIDS population as infection in the paediatric HIV and AIDS group, although bearing some similarities, demonstrates some important differences.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. Central Nervous System Infections / diagnosis
  • [MeSH-minor] AIDS Dementia Complex / diagnosis. AIDS Dementia Complex / radiography. Adult. Cytomegalovirus Infections / diagnosis. Cytomegalovirus Infections / radiography. Encephalitis / diagnosis. Encephalitis / radiography. HIV-1. Humans. Leukoencephalopathy, Progressive Multifocal / diagnosis. Leukoencephalopathy, Progressive Multifocal / radiography. Magnetic Resonance Imaging / methods. Meningitis, Cryptococcal / diagnosis. Meningitis, Cryptococcal / radiography. Neurosyphilis / diagnosis. Neurosyphilis / radiography. Tomography, X-Ray Computed / methods. Toxoplasmosis, Cerebral / diagnosis. Toxoplasmosis, Cerebral / radiography. Tuberculosis, Central Nervous System / diagnosis. Tuberculosis, Central Nervous System / radiography

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16679111.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 21
  •  go-up   go-down


9. Pels H, Montesinos-Rongen M, Schaller C, Schlegel U, Schmidt-Wolf IG, Wiestler OD, Deckert M: VH gene analysis of primary CNS lymphomas. J Neurol Sci; 2005 Feb 15;228(2):143-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VH gene analysis of primary CNS lymphomas.
  • Primary CNS lymphomas (PCNSL) are highly malignant non-Hodgkin's lymphomas of B cell origin associated with a poor prognosis.
  • These neoplasms show variable sensitivity to radio- and chemotherapy.
  • A molecular basis for these differences in treatment responses has not yet been established for primary CNS lymphomas in a comprehensive series of patients.
  • [MeSH-major] Brain Neoplasms / genetics. Drug Resistance, Neoplasm / genetics. Gene Rearrangement, B-Lymphocyte / genetics. Genes, Immunoglobulin / genetics. Immunoglobulins / genetics. Lymphoma, Non-Hodgkin / genetics
  • [MeSH-minor] Adult. Aged. DNA Mutational Analysis. Disease Progression. Female. Gene Frequency. Genetic Markers / genetics. Genetic Markers / immunology. Genetic Predisposition to Disease / genetics. Genetic Testing. Humans. Male. Middle Aged. Mutation / genetics. Predictive Value of Tests. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15694195.001).
  • [ISSN] 0022-510X
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Immunoglobulins
  •  go-up   go-down


10. Finelli PF, Naik K, DiGiuseppe JA, Prasad A: Primary lymphoma of CNS, mycophenolate mofetil and lupus. Lupus; 2006;15(12):886-8
Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of CNS, mycophenolate mofetil and lupus.
  • Lymphoproliferative disorders are known to complicate immunosuppressive therapy and two cases of primary lymphoma of CNS (PCNSL) have previously been described in association with mycophenolate mofetil (MMF) treatment.
  • [MeSH-major] Central Nervous System Neoplasms / chemically induced. Immunosuppressive Agents / adverse effects. Lupus Erythematosus, Systemic / drug therapy. Lymphoma / chemically induced. Mycophenolic Acid / analogs & derivatives
  • [MeSH-minor] Adult. Diffusion Magnetic Resonance Imaging. Fatal Outcome. Female. Humans. Immunosuppression / adverse effects

  • Genetic Alliance. consumer health - Lupus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17211996.001).
  • [ISSN] 0961-2033
  • [Journal-full-title] Lupus
  • [ISO-abbreviation] Lupus
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; HU9DX48N0T / Mycophenolic Acid
  •  go-up   go-down


11. Dulai MS, Park CY, Howell WD, Smyth LT, Desai M, Carter DM, Vogel H: CNS T-cell lymphoma: an under-recognized entity? Acta Neuropathol; 2008 Mar;115(3):345-56
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS T-cell lymphoma: an under-recognized entity?
  • The incidence of CNS lymphoma has increased significantly in the past 30 years, primarily in the elderly and immunocompromised.
  • While T-cell lymphomas comprise 15-20% of systemic lymphomas, they comprise less than 4% of primary CNS lymphomas, suggesting that they may be under-recognized compared to their systemic counterparts.
  • We conclude that because of the high degree of overlap in cytomorphologic and immunophenotypic features between T-cell lymphoma and reactive infiltrates, T-cell lymphoma may not be recognized unless studies for T-cell receptor gene rearrangements are performed for CNS lesions composed of a polymorphous but predominantly T-cell infiltrate.
  • [MeSH-major] Brain Diseases / pathology. Central Nervous System Neoplasms / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Immunohistochemistry. In Situ Hybridization. Magnetic Resonance Imaging. Male. Middle Aged. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18196250.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Murray G, Jiménez L, Báez F, Colón-Castillo LE, Brau RH: Descriptive profile of surgically-confirmed adult central nervous system tumors in Puerto Rico. P R Health Sci J; 2009 Dec;28(4):317-28

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive profile of surgically-confirmed adult central nervous system tumors in Puerto Rico.
  • INTRODUCTION: Published studies regarding the incidence of central nervous system (CNS) tumors in Puerto Rico (PR) are exceedingly rare.
  • The general understanding is that the incidence of these tumors in Puerto Rico is similar to the one found in the United States of America (USA).
  • The objective of this study is to describe the specific profile of all the CNS tumors that are surgically intervened in Puerto Rico, through the creation of a database.
  • METHODS: A retrospective analysis of all the surgical procedures from January 1, 2002 to May 31, 2006 for adult CNS tumors in Puerto Rico was performed.
  • The information was organized to form a database of all the CNS neoplasms.
  • RESULTS: A total of 1,018 procedures for CNS tumors were performed on 1,005 patients.
  • The incidence rate of surgically intervened CNS tumors in Puerto Rico is 6 per 100,000 people.
  • CNS tumors were more common in women than in men (58% vs. 42%), respectively.
  • CONCLUSIONS: Our results reflect a unique histopathological distribution of operated CNS tumors in Puerto Rico.
  • In this series, primary tumors are more common than metastatic tumors.
  • Benign histological tumors were more frequent than more malignant variants.
  • Although this study reflects only the histologically diagnosed tumors, it is headway towards diagnosing the incidence of all CNS tumors in Puerto Rico.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Central Nervous System Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Puerto Rico. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999240.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


13. Kamoshima Y, Sawamura Y, Ikeda J, Shirato H, Aoyama H: Late recurrence and salvage therapy of CNS germinomas. J Neurooncol; 2008 Nov;90(2):205-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late recurrence and salvage therapy of CNS germinomas.
  • Central nervous system (CNS) germinoma is a curable tumor and its recurrence rate after initial therapy may be approximately 10% or higher.
  • All patients had been tumor-free for at least 6 months after the initial treatment.
  • Seventeen patients (68%) were salvaged and were tumor-free at the final observation.
  • At first recurrence, 11 patients were treated using radiation therapy with or without surgery and 7 out of the 11 patients died due to the recurrent tumor.
  • On the other hand, 13 patients who received salvage chemotherapy and radiotherapy were tumor-free at the last follow-up.
  • In conclusion, late recurrence is not a rare event in patients with CNS germinoma.
  • [MeSH-major] Central Nervous System Neoplasms / prevention & control. Germinoma / prevention & control. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Child. Female. Follow-Up Studies. Humans. Male. Remission Induction. Retrospective Studies. Secondary Prevention. Time Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604473.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


14. Wolf RL, Wang J, Wang S, Melhem ER, O'Rourke DM, Judy KD, Detre JA: Grading of CNS neoplasms using continuous arterial spin labeled perfusion MR imaging at 3 Tesla. J Magn Reson Imaging; 2005 Oct;22(4):475-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grading of CNS neoplasms using continuous arterial spin labeled perfusion MR imaging at 3 Tesla.
  • MATERIALS AND METHODS: CASL perfusion images were obtained preoperatively in 26 patients with brain neoplasms (19 high-grade gliomas (HGGs; WHO grades 3 and 4) and seven low-grade gliomas (LGGs; WHO grades 1 and 2)).
  • The mean and maximum tumor blood flow (TBF and TBFmax) were calculated in the neoplasm, including surrounding infiltrating tumor vs. edema.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioma / diagnosis. Magnetic Resonance Angiography / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Spin Labels

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16161080.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K23 NS43381; United States / NINDS NIH HHS / NS / NS045839; United States / NCRR NIH HHS / RR / RR002305
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Spin Labels
  •  go-up   go-down


15. Gläsker S, Klingler JH, Müller K, Würtenberger C, Hader C, Zentner J, Neumann HP, Velthoven VV: Essentials and pitfalls in the treatment of CNS hemangioblastomas and von Hippel-Lindau disease. Cent Eur Neurosurg; 2010 May;71(2):80-7
MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Essentials and pitfalls in the treatment of CNS hemangioblastomas and von Hippel-Lindau disease.
  • Hemangioblastomas are rare CNS tumors, which are mostly located in the posterior fossa or spinal cord and occasionally in spinal nerves.
  • They can occur sporadically or as a component tumor of von Hippel-Lindau (VHL) disease, an autosomal dominant tumor syndrome.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / surgery. Hemangioblastoma / pathology. Hemangioblastoma / surgery. Neurosurgical Procedures / methods. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / surgery. von Hippel-Lindau Disease / pathology. von Hippel-Lindau Disease / surgery
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Georg Thieme Verlag KG Stuttgart . New York.
  • (PMID = 20229452.001).
  • [ISSN] 1868-4912
  • [Journal-full-title] Central European neurosurgery
  • [ISO-abbreviation] Cent Eur Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Kosmas C, Tsakonas G, Mylonakis N: Treatment strategies in CNS metastases. Expert Opin Pharmacother; 2008 Aug;9(12):2087-98
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment strategies in CNS metastases.
  • BACKGROUND: CNS metastases constitute the most common brain malignancy in adults and, therefore, represent a challenging issue in cancer treatment.
  • METHODS: Therapeutic approaches in treating CNS metastases include surgery, radiotherapy and systemic chemotherapy, and are reviewed through a critical evaluation of published recent literature; however, in the majority of most common malignancies spreading to the CNS, treatment remains largely palliative and rarely curative, as is the case for other metastastic sites.
  • CONCLUSIONS: It is anticipated that a multidisciplinary approach with rapid integration of new treatment strategies is required for the treatment of patients developing CNS metastases, ultimately aiming to prolong survival, preserve neurologic function and improve quality of life.
  • [MeSH-major] Brain Neoplasms
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Breast Neoplasms / pathology. Combined Modality Therapy. Female. Humans. Lung Neoplasms / pathology. Male. Melanoma / pathology. Radiation-Sensitizing Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18671464.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents
  • [Number-of-references] 81
  •  go-up   go-down


17. Boman KK, Hovén E, Anclair M, Lannering B, Gustafsson G: Health and persistent functional late effects in adult survivors of childhood CNS tumours: a population-based cohort study. Eur J Cancer; 2009 Sep;45(14):2552-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health and persistent functional late effects in adult survivors of childhood CNS tumours: a population-based cohort study.
  • Survivors of central nervous system (CNS) tumours are particularly vulnerable to tumour- and treatment-related disability.
  • We present the incidence of specific and overall functional and health-related late effects in a national adult survivor cohort.
  • Least late effects were found for other specified/unspecified CNS tumours (including meningeoma and nerve sheath tumours), and for astrocytoma.
  • Comparisons with controls confirm persistent disability in multiple functional domains in adult CNS tumour survivors.
  • [MeSH-major] Central Nervous System Neoplasms / complications. Health Status. Survivors
  • [MeSH-minor] Activities of Daily Living. Adolescent. Adult. Age Factors. Case-Control Studies. Child. Child, Preschool. Cognition Disorders / epidemiology. Cohort Studies. Female. Humans. Incidence. Male. Pain / epidemiology. Quality of Life. Risk Factors. Self Care. Sensation Disorders / epidemiology. Sweden / epidemiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19616428.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


18. Arora RS, Alston RD, Eden TO, Estlin EJ, Moran A, Geraci M, Birch JM: Are reported increases in incidence of primary CNS tumours real? An analysis of longitudinal trends in England, 1979-2003. Eur J Cancer; 2010 Jun;46(9):1607-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are reported increases in incidence of primary CNS tumours real? An analysis of longitudinal trends in England, 1979-2003.
  • Reported increases in the incidence of CNS tumours in the developed world in the 1970s to 1990s have been a cause for concern and debate.
  • Using high-quality national cancer registration data, we have analysed incidence trends for each major histological subgroup of CNS tumour (2000 World Health Organisation (WHO) classification) registered in those aged 0-84 years for the whole of England during the period 1979 through 2003.
  • 134,509 primary CNS tumours of malignant, benign and uncertain behaviour located in the brain, meninges, spinal cord, cranial nerves, other parts of the central nervous system and in the pituitary and pineal glands were registered.
  • In summary, we present the single largest nationwide study on the longitudinal incidence trends of CNS tumours.
  • Much of the initial increase can be attributed to the emergence of much more widely available neuroimaging, while the most recent incidence changes for specific sub-groups of CNS tumours appear to be due to greater diagnostic specificity leading to a shift in registered categories.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child. Child, Preschool. England / epidemiology. Female. Humans. Incidence. Infant. Longitudinal Studies. Male. Middle Aged. Registries

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20194015.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


19. Arora RS, Alston RD, Eden TO, Estlin EJ, Moran A, Birch JM: Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England. Neuro Oncol; 2009 Aug;11(4):403-13
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England.
  • Around 25% of all tumors in those 0-14 years of age and 9% in those 15-24 years of age involve the CNS.
  • In adults 25-84 years of age, the proportion of CNS tumors is 2%; 5-year overall survival is 10%-15%; and survivors have considerable morbidity.
  • Comprehensive up-to-date population-based incidence data on these tumors are lacking.
  • We present incidence rates for primary CNS tumors based on data derived from the high-quality national cancer registration system in England.
  • A total of 54,336 CNS tumors of malignant, benign, and uncertain behavior were registered across the whole of England from 1995 through 2003.
  • This is higher than previously reported for England because it includes nonmalignant CNS tumors and hence gives a more accurate picture of burden of disease.
  • In this article, we describe the changing patterns in the epidemiology of primary CNS tumors in these three age groups with respect to sex, tumor behavior, and histology using the current WHO classification.
  • [MeSH-major] Brain Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. England / epidemiology. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Risk Factors. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):168-74 [10634382.001]
  • [Cites] Br J Cancer. 2007 Dec 3;97(11):1588-94 [17987032.001]
  • [Cites] Am J Otol. 2000 Sep;21(5):690-4 [10993460.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1548-56 [11920513.001]
  • [Cites] Br J Neurosurg. 2002 Apr;16(2):140-5 [12046732.001]
  • [Cites] Med Pediatr Oncol. 2002 Sep;39(3):190-4 [12210449.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] J Neurooncol. 2002 Oct;60(1):61-9 [12416547.001]
  • [Cites] Br J Cancer. 2002 Nov 18;87(11):1267-74 [12439716.001]
  • [Cites] Dev Med Child Neurol. 2003 May;45(5):308-14 [12729144.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):168-78 [12816723.001]
  • [Cites] Int J Cancer. 2004 Jan 20;108(3):450-5 [14648713.001]
  • [Cites] Neuroepidemiology. 2004 May-Jun;23(3):101-9 [15084778.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii12-7 [15146034.001]
  • [Cites] Mayo Clin Proc. 1978 Oct;53(10):641-3 [713594.001]
  • [Cites] J Neurosurg. 1985 Dec;63(6):881-9 [4056902.001]
  • [Cites] Zentralbl Neurochir. 1987;48(2):120-3 [3673352.001]
  • [Cites] Childs Nerv Syst. 1991 Aug;7(4):177-82 [1933913.001]
  • [Cites] Am J Epidemiol. 1992 Jun 15;135(12):1349-57 [1510081.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Sep;41(3):359-64 [7893282.001]
  • [Cites] J Neurooncol. 1995;25(1):67-71 [8523091.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):827-33 [8608471.001]
  • [Cites] Neurol Med Chir (Tokyo). 1999 Jan;39(1):59-107 [10093464.001]
  • [Cites] Laryngoscope. 1999 May;109(5):736-40 [10334223.001]
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):996-1001 [15986431.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):1-11 [16443943.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):27-37 [16443945.001]
  • [Cites] Acta Neurochir (Wien). 2006 Aug;148(8):865-71; discussion 871 [16791430.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(13):2064-80 [16919771.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4754-7 [16966685.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):81-9 [17482475.001]
  • [Cites] Health Stat Q. 2007 Autumn;(35):78-83 [17894201.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Apr;85(4):1420-5 [10770176.001]
  • (PMID = 19033157.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2743220
  •  go-up   go-down


20. Reismüller B, Azizi AA, Peyrl A, Heinrich M, Gruber-Olipitz M, Luckner D, Rothschild KV, Slavc I: Feasibility and tolerability of bevacizumab in children with primary CNS tumors. Pediatr Blood Cancer; 2010 May;54(5):681-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility and tolerability of bevacizumab in children with primary CNS tumors.
  • BACKGROUND: Bevacizumab, an antibody to the vascular endothelial growth factor, has demonstrated anti-cancer activity in a number of solid tumors.
  • Fear of intratumoral hemorrhage, however, has slowed its introduction into the treatment of central nervous system (CNS) tumors.
  • Most patients had recurrent/progressive disease, 25 high-grade and 5 low-grade tumors.
  • CONCLUSIONS: Bevacizumab appears to be safe for children with primary CNS tumors.
  • Hypertension occurred less frequently than in adult patients.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Central Nervous System Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bevacizumab. Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Child. Child, Preschool. Drug-Related Side Effects and Adverse Reactions. Feasibility Studies. Female. Humans. Infant. Lymphopenia / chemically induced. Male. Proteinuria / chemically induced. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20066713.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


21. Morris EB, Gajjar A, Okuma JO, Yasui Y, Wallace D, Kun LE, Merchant TE, Fouladi M, Broniscer A, Robison LL, Hudson MM: Survival and late mortality in long-term survivors of pediatric CNS tumors. J Clin Oncol; 2007 Apr 20;25(12):1532-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and late mortality in long-term survivors of pediatric CNS tumors.
  • PURPOSE: To describe the pattern of survival and late mortality among contemporary long-term survivors of pediatric CNS tumor.
  • PATIENTS AND METHODS: The study population comprised 643 pediatric patients with primary CNS tumor treated at St Jude Children's Research Hospital (Memphis, TN) from 1985 to 2000 who survived > or = 5 years from diagnosis.
  • Patients were classified according to primary tumor type, location of tumor, and survival.
  • A significant difference in the survival rates according to original tumor type (P = .001) was seen.
  • Sixty-six (10%) of 643 patients experienced late mortality: 38 patients (58%) died of progressive disease while 14 patients (21%) died of second malignant tumor.
  • Twelve patients (18%), predominantly with diencephalic tumor location, died of a specific medical cause: cardiovascular disease (n = 2), cerebrovascular accident (n = 1), metabolic collapse and/or sepsis (n = 7), respiratory failure (n = 1), or shunt malfunction (n = 1).
  • CONCLUSION: Late mortality occurs in a substantial number of long-term survivors of pediatric CNS tumors and is most influenced by the initial tumor histopathology.
  • [MeSH-major] Cause of Death. Central Nervous System Neoplasms / mortality. Survivors / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Child. Child, Preschool. Cohort Studies. Disease Progression. Disease-Free Survival. Female. Humans. Incidence. Male. Neoplasm Staging. Prognosis. Registries. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17442996.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 21765
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Omuro AM, DeAngelis LM, Yahalom J, Abrey LE: Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology; 2005 Jan 11;64(1):69-74
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up.
  • OBJECTIVE: To assess the efficacy and safety of a preradiation chemotherapy regimen in patients with primary CNS lymphoma (PCNSL), with emphasis on long-term outcomes.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Lymphoma / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain / drug effects. Brain / radiation effects. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Female. Follow-Up Studies. Humans. Injections, Spinal. Male. Methotrexate / administration & dosage. Methotrexate / therapeutic use. Middle Aged. Procarbazine / administration & dosage. Procarbazine / therapeutic use. Prospective Studies. Survival Rate. Thiotepa / administration & dosage. Thiotepa / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642906.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 905Z5W3GKH / Thiotepa; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


23. Bergler-Czop B, Lis-Swiety A, Brzezińska-Wcisło L: Scleroderma linearis: hemiatrophia faciei progressiva (Parry-Romberg syndrom) without any changes in CNS and linear scleroderma "en coup de sabre" with CNS tumor. BMC Neurol; 2009;9:39
Genetic Alliance. consumer health - Scleroderma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scleroderma linearis: hemiatrophia faciei progressiva (Parry-Romberg syndrom) without any changes in CNS and linear scleroderma "en coup de sabre" with CNS tumor.
  • CASE PRESENTATION: We present two cases of a disease: a case of a 49-year-old woman with a typical image of hemifacial atrophy, without any changes of the nervous system and a case of a 33-year-old patient with an "en coup de sabre" scleroderma and with CNS tumor.
  • In the patient diagnosed with Parry-Romberg syndrome, with Borrelia burgdoferi infection and with minor neurological symptoms, despite a four-year case history, there was a lack of proper diagnosis and treatment.In the second patient only skin changes without any neurological symptoms could be observed and only a precise neurological diagnosis revealed the presence of CNS tumor.
  • [MeSH-minor] Adult. Borrelia burgdorferi. Cerebral Ventricle Neoplasms / complications. Cerebral Ventricle Neoplasms / pathology. Diagnosis, Differential. Electromyography. Female. Humans. Lyme Disease / complications. Magnetic Resonance Imaging. Middle Aged. Neurologic Examination. Tomography, Spiral Computed. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Linear scleroderma (subtype).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Rheumatol. 2003 Sep;30(9):1997-2004 [12966605.001]
  • [Cites] BMC Dermatol. 2001;1:9 [11741509.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Apr;18(4):751-7 [9127045.001]
  • [Cites] J Pediatr. 2005 Mar;146(3):429-31 [15756237.001]
  • [Cites] J Am Acad Dermatol. 2006 Feb;54(2):227-33 [16443052.001]
  • [Cites] Childs Nerv Syst. 2006 Apr;22(4):409-15 [16247619.001]
  • [Cites] Neurology. 2003 Sep 9;61(5):674-6 [12963760.001]
  • [Cites] Hautarzt. 2006 Oct;57(10):905-6 [16960731.001]
  • [Cites] J Am Acad Dermatol. 2007 Feb;56(2):257-63 [17147965.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Apr;29(4):714-5 [18202229.001]
  • [Cites] Pediatr Neurol. 2001 Nov;25(5):416-8 [11744320.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 May;74(5):661-4 [12700315.001]
  • [Cites] Klin Monbl Augenheilkd. 2003 Jun;220(6):427-32 [12830399.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Sep;27(8):1729-31 [16971623.001]
  • (PMID = 19635150.001).
  • [ISSN] 1471-2377
  • [Journal-full-title] BMC neurology
  • [ISO-abbreviation] BMC Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2723072
  •  go-up   go-down


24. Holfort SK, Lindegaard J, Isager P, Prause JU, Heegaard S: CNS metastasis from malignant uveal melanoma: a clinical and histopathological characterisation. Br J Ophthalmol; 2009 May;93(5):641-4
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS metastasis from malignant uveal melanoma: a clinical and histopathological characterisation.
  • AIM: To characterise uveal melanoma that has metastasised to the central nervous system (CNS).
  • All patients with malignant uveal melanoma and metastasis to the CNS were identified.
  • RESULTS: Sixteen patients with CNS metastasis were identified.
  • The majority of CNS metastases were located in the frontal and parietal lobes.
  • Five patients had exclusively metastasis to the CNS.
  • The average time from diagnosis of primary tumour to symptoms of CNS metastasis was 91 months.
  • The average time from the initial CNS symptoms to death was 20 months.
  • CONCLUSION: The proportion of uveal melanoma patients having CNS metastasis was 0.7%.
  • Eleven patients had multiple organ metastases, and the average time from the initial CNS symptoms to death was 8 months.
  • Five patients had metastasis to the CNS solely, and the average time from the initial CNS symptoms to death was 57 months.
  • [MeSH-major] Brain Neoplasms / secondary. Melanoma / secondary. Uveal Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Denmark / epidemiology. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Registries. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19091854.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


25. Carroll TJ, Horowitz S, Shin W, Mouannes J, Sawlani R, Ali S, Raizer J, Futterer S: Quantification of cerebral perfusion using the "bookend technique": an evaluation in CNS tumors. Magn Reson Imaging; 2008 Dec;26(10):1352-9
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantification of cerebral perfusion using the "bookend technique": an evaluation in CNS tumors.
  • We have compared the quantitative SE-EPI with GRE-EPI in a series of patients with central nervous system (CNS) tumors.
  • We conclude that measuring qCBV using the bookend technique with SE-EPI images is possible and may be a viable alternative to GRE-EPI in the evaluation of CNS tumors.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stroke. 1984 Jul-Aug;15(4):635-41 [6611613.001]
  • [Cites] J Comput Assist Tomogr. 1980 Dec;4(6):727-36 [6971299.001]
  • [Cites] Magn Reson Med. 1992 Jan;23(1):21-30 [1734180.001]
  • [Cites] Magn Reson Med. 1991 Dec;22(2):293-9; discussion 300-3 [1812360.001]
  • [Cites] Magn Reson Med. 1994 Jun;31(6):601-10 [8057812.001]
  • [Cites] Radiology. 1994 Dec;193(3):637-41 [7972800.001]
  • [Cites] Radiology. 1996 Oct;201(1):106-12 [8816529.001]
  • [Cites] Magn Reson Med. 1996 Nov;36(5):715-25 [8916022.001]
  • [Cites] Magn Reson Med. 1996 Nov;36(5):726-36 [8916023.001]
  • [Cites] Magn Reson Med. 1996 Dec;36(6):858-67 [8946351.001]
  • [Cites] Magn Reson Med. 1997 Oct;38(4):591-603 [9324327.001]
  • [Cites] Top Magn Reson Imaging. 2004 Oct;15(5):279-89 [15627003.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Feb;26(2):266-73 [15709123.001]
  • [Cites] J Magn Reson Imaging. 2005 May;21(5):512-9 [15834910.001]
  • [Cites] Radiology. 2006 Feb;238(2):658-67 [16396838.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Apr;27(4):859-67 [16611779.001]
  • [Cites] Magn Reson Med. 2006 Jul;56(1):138-45 [16767742.001]
  • [Cites] Magn Reson Med. 2007 Dec;58(6):1232-41 [17969025.001]
  • [Cites] Magn Reson Med. 1999 Nov;42(5):952-62 [10542355.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Aug;22(7):1306-15 [11498419.001]
  • [Cites] Magn Reson Med. 2001 Oct;46(4):735-47 [11590650.001]
  • [Cites] Magn Reson Med. 2002 Jun;47(6):1110-20 [12111957.001]
  • [Cites] Magn Reson Med. 2002 Jun;47(6):1202-10 [12111967.001]
  • [Cites] Radiology. 2003 May;227(2):593-600 [12663823.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 May;25(5):746-55 [15140713.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Oct;25(9):1524-32 [15502131.001]
  • [Cites] Biophys J. 1974 Aug;14(8):583-606 [4853385.001]
  • [Cites] Magn Reson Med. 1990 May;14(2):249-65 [2345506.001]
  • (PMID = 18538523.001).
  • [ISSN] 0730-725X
  • [Journal-full-title] Magnetic resonance imaging
  • [ISO-abbreviation] Magn Reson Imaging
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS049395-01A2; United States / NIBIB NIH HHS / EB / T32 EB005170-03; United States / NIBIB NIH HHS / EB / T32 EB005170; United States / NINDS NIH HHS / NS / R01NS049395-01A2; United States / NIBIB NIH HHS / EB / EB005170-03; United States / NINDS NIH HHS / NS / R01 NS049395-01A2; United States / NINDS NIH HHS / NS / R01 NS049395
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ NIHMS81510; NLM/ PMC2612563
  •  go-up   go-down


26. Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, LaRocca R, Grant B, DeAngelis LM, Abrey LE: Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol; 2007 Oct 20;25(30):4730-5
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
  • PURPOSE: Our goals were to evaluate the safety of adding rituximab to methotrexate (MTX)-based chemotherapy for primary CNS lymphoma, determine whether additional cycles of induction chemotherapy improve the complete response (CR) rate, and examine effectiveness and toxicity of reduced-dose whole-brain radiotherapy (WBRT) after CR.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Cranial Irradiation. Immunotherapy. Lymphoma / drug therapy. Lymphoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Combined Modality Therapy. Cytarabine / administration & dosage. Female. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Procarbazine / administration & dosage. Prospective Studies. Remission Induction. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2008 Jan 10;26(2):340
  • (PMID = 17947720.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 35S93Y190K / Procarbazine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


27. Syczewska M, Dembowska-Bagińska B, Perek-Polnik M, Kalinowska M, Perek D: Postural sway in children and young adults, survivors of CNS tumours. Adv Med Sci; 2008;53(2):256-62
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postural sway in children and young adults, survivors of CNS tumours.
  • MATERIAL AND METHODS: The balance assessment was performed on patients who completed the treatment of CNS tumours and were disease-free at the time of the study.
  • CONCLUSIONS: These results suggest that the repair mechanisms of the CNS could overcome the problems inflicted by the illness and therapy.
  • [MeSH-major] Brain Neoplasms / physiopathology. Postural Balance / physiology. Sensation Disorders / physiopathology. Spinal Cord Neoplasms / physiopathology. Survivors
  • [MeSH-minor] Adolescent. Age of Onset. Child. Child, Preschool. Female. Humans. Male. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18762469.001).
  • [ISSN] 1896-1126
  • [Journal-full-title] Advances in medical sciences
  • [ISO-abbreviation] Adv Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  •  go-up   go-down


28. Ahuja G, Cuellar S, Choudhry I, Setty S, Yao M, Villano JL: Complete response of CNS-involved olfactory neuroendocrine tumor using multimodal therapy. Onkologie; 2008 Mar;31(3):119-21
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of CNS-involved olfactory neuroendocrine tumor using multimodal therapy.
  • INTRODUCTION: Locally advanced tumors in the olfactory area commonly have central nervous system (CNS) involvement and are often incurable.
  • CASE REPORT: We report the treatment of a 25-year-old male patient who presented with a large, neuroendocrine tumor arising from the ethmoid complex.
  • An endoscopic nasal biopsy demonstrated a poorly differentiated neuroendocrine tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / therapy. Ethmoid Bone / pathology. Neuroendocrine Tumors / therapy. Radiotherapy, Adjuvant. Skull Neoplasms / therapy
  • [MeSH-minor] Adult. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Humans. Male. Organization and Administration

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18322415.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


29. Yang JH, Wu SL: Multiple sclerosis preceding CNS lymphoma: a case report. Acta Neurol Taiwan; 2007 Jun;16(2):92-7
MedlinePlus Health Information. consumer health - Multiple Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple sclerosis preceding CNS lymphoma: a case report.
  • Primary central nervous system (CNS) lymphoma is usually a diffuse large B-cell non-Hodgkin's lymphoma that originates in the brain, spinal cord, leptomeninges, or eyes.
  • We report a 33-year-old patient who was diagnosed to have multiple sclerosis initially and a CNS lymphoma was noted 38 months later.
  • Primary CNS lymphoma is a potential complication of chronic immunosuppression.
  • These agents might contribute to the occurrence of a primary CNS lymphoma.
  • On the other hand, a demyelinating disease may have preceded the diagnosis of primary CNS lymphoma.
  • A possibility of neoplastic transformation in CNS inflammatory diseases such as multiple sclerosis may occur.
  • The association of coexistent primary CNS lymphoma and multiple sclerosis may be more than coincidental.
  • [MeSH-major] Brain Neoplasms / etiology. Lymphoma / etiology. Multiple Sclerosis / complications
  • [MeSH-minor] Adult. Brain / pathology. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17685133.001).
  • [ISSN] 1028-768X
  • [Journal-full-title] Acta neurologica Taiwanica
  • [ISO-abbreviation] Acta Neurol Taiwan
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


30. Thuppal S, Propp JM, McCarthy BJ: Average years of potential life lost in those who have died from brain and CNS tumors in the USA. Neuroepidemiology; 2006;27(1):22-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Average years of potential life lost in those who have died from brain and CNS tumors in the USA.
  • The aim of this study was to quantify the impact of all primary malignant and nonmalignant brain and central nervous system (CNS) tumors on mortality in the USA in terms of years of life lost, an indicator of premature mortality in the population.
  • Person-years of potential life lost (PYPLL) and average years of potential life lost (AYPLL) were calculated for all deaths due to brain and CNS tumors as an underlying cause.
  • 16,819 deaths due to brain and CNS tumors occurred in 2001, leading to a total loss of 357,483 person-years of life and an average loss of 21.3 years (AYPLL).
  • Malignant tumors led to an AYPLL of 25 years, which was significantly higher than the AYPLL of 19 years due to nonmalignant tumors.
  • The relative impact of tumors arising in the various anatomical sites in the brain and CNS among adults and among children was not similar.
  • The use of population survival indicators, such as PYPLL and AYPLL, will help better understanding of the effect of racial, ethnic, gender and age differences on the mortality due to malignant and nonmalignant brain and CNS tumors.
  • [MeSH-major] Central Nervous System Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Brain Neoplasms / mortality. Child. Female. Humans. Male. Middle Aged. Prevalence. Registries. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770081.001).
  • [ISSN] 0251-5350
  • [Journal-full-title] Neuroepidemiology
  • [ISO-abbreviation] Neuroepidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


31. Zhang H, Luo XQ, Zhang P, Huang LB, Zheng YS, Wu J, Zhou H, Qu LH, Xu L, Chen YQ: MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One; 2009;4(11):e7826
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia.
  • BACKGROUND: Recent reports have indicated that microRNAs (miRNAs) play a critical role in malignancies, and regulations in the progress of adult leukemia.
  • The most highly expressed miRNAs in pediatric ALL were miR-34a, miR-128a, miR-128b, and miR-146a, while the highly expressed miRNAs in pediatric AML were miR-100, miR-125b, miR-335, miR-146a, and miR-99a, which are significantly different from those reported for adult CLL and AML. miR-125b and miR-126 may serve as favorable prognosticators for M3 and M2 patients, respectively.
  • Importantly, we identified a "miRNA cascade" associated with central nervous system (CNS) relapse in ALL.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Leukemia / diagnosis. Leukemia / pathology. MicroRNAs

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2003 Apr 4;113(1):25-36 [12679032.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):438-42 [12600936.001]
  • [Cites] J Pediatr (Rio J). 2003 Mar-Apr;79(2):149-58 [14502336.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Feb;39(2):167-9 [14695998.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Genes Dev. 2004 Mar 1;18(5):504-11 [15014042.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):893-901 [15329427.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):769-73 [15685193.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] Nature. 2005 Mar 17;434(7031):338-45 [15735639.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1768-71 [16251533.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):167-73 [16616063.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7390-4 [16885332.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19971-6 [18056805.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2825-32 [18089852.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3183-9 [18187662.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3945-50 [18308931.001]
  • [Cites] Blood. 2008 May 15;111(10):5078-85 [18337557.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15535-40 [18832181.001]
  • [Cites] J Exp Med. 2008 Oct 27;205(11):2499-506 [18936236.001]
  • [Cites] J Clin Oncol. 2008 Nov 1;26(31):5078-87 [18809607.001]
  • [Cites] Leukemia. 2009 Feb;23(2):313-22 [18923441.001]
  • [Cites] Dev Biol. 1999 Dec 15;216(2):671-80 [10642801.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):179-81 [12525506.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • (PMID = 19915715.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2773830
  •  go-up   go-down


32. Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL: Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol; 2008 Jan 1;26(1):96-105
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein biomarker identification in the CSF of patients with CNS lymphoma.
  • PURPOSE: Elucidation of the CSF proteome may yield insights into the pathogenesis of CNS disease.
  • We tested the hypothesis that individual CSF proteins distinguish CNS lymphoma from benign focal brain lesions.
  • METHODS: We used a liquid chromatography/mass spectrometry-based method to differentially quantify and identify several hundred CSF proteins in CNS lymphoma and control patients.
  • ATIII RNA transcripts were identified within CNS lymphomas, and ATIII protein was localized selectively to tumor neovasculature.
  • We propose that the discovery of CSF protein biomarkers will facilitate early and noninvasive diagnosis in patients with lesions not amenable to brain biopsy, as well as provide improved surrogates of prognosis and treatment response in CNS lymphoma and brain metastasis.
  • [MeSH-major] Biomarkers, Tumor / cerebrospinal fluid. Brain Neoplasms / cerebrospinal fluid. Lymphoma / cerebrospinal fluid. Neoplasm Proteins / cerebrospinal fluid
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antithrombin III / genetics. Antithrombin III / metabolism. Case-Control Studies. Chromatography, Liquid. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoblotting. Immunoenzyme Techniques. Leukemia, Myeloid / cerebrospinal fluid. Leukemia, Myeloid / pathology. Lymphoma, B-Cell / cerebrospinal fluid. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / cerebrospinal fluid. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / cerebrospinal fluid. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / cerebrospinal fluid. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Proteomics. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Feb;17(2):554-60 [10080599.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3575-82 [15284095.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):705-17, vii [16083831.001]
  • [Cites] Mol Cell Proteomics. 2005 Sep;4(9):1341-9 [15970584.001]
  • [Cites] Dis Markers. 2006;22(1-2):3-26 [16410649.001]
  • [Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]
  • [Cites] J Biol Chem. 2006 Dec 8;281(49):37302-10 [17040907.001]
  • [Cites] Expert Rev Mol Med. 2006;8(31):1-19 [17156576.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Anal Chem. 2003 Sep 15;75(18):4818-26 [14674459.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2053-63 [12466122.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Curr Opin Neurol. 2000 Dec;13(6):641-8 [11148663.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]
  • [Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]
  • [Cites] Br J Haematol. 2004 Jul;126(2):202-8 [15238140.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2922-7 [15131026.001]
  • [Cites] Bioinformatics. 2004 Mar 22;20(5):777-85 [14751995.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1):72-5 [17236490.001]
  • [CommentIn] J Clin Oncol. 2009 May 1;27(13):2302-3; author reply 2303-4 [19332721.001]
  • (PMID = 18056677.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA100291
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 9000-94-6 / Antithrombin III
  • [Other-IDs] NLM/ NIHMS612770; NLM/ PMC4134101
  •  go-up   go-down


33. Levin N, Soffer D, Grissaru S, Aizikovich N, Gomori JM, Siegal T: Primary T-cell CNS lymphoma presenting with leptomeningeal spread and neurolymphomatosis. J Neurooncol; 2008 Oct;90(1):77-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary T-cell CNS lymphoma presenting with leptomeningeal spread and neurolymphomatosis.
  • Primary CNS lymphoma (PCNSL), a rare form of non-Hodgkin lymphoma that is confined to the brain, is usually of B-cell origin.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma, T-Cell / complications. Lymphoma, T-Cell / pathology. Meningeal Neoplasms / secondary. Peripheral Nervous System Diseases / etiology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Pseudotumor Cerebri / pathology. Vasculitis / pathology

  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18592137.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


34. Grisariu S, Avni B, Batchelor TT, van den Bent MJ, Bokstein F, Schiff D, Kuittinen O, Chamberlain MC, Roth P, Nemets A, Shalom E, Ben-Yehuda D, Siegal T, International Primary CNS Lymphoma Collaborative Group: Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood; 2010 Jun 17;115(24):5005-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report.
  • The International Primary CNS Lymphoma Collaborative Group retrospectively analyzed 50 patients assembled from 12 centers in 5 countries over a 16-year period.
  • [MeSH-major] Leukemia. Leukemic Infiltration. Lymphoma, Non-Hodgkin. Nervous System Neoplasms
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Cerebrospinal Fluid / cytology. Cooperative Behavior. Female. Humans. International Cooperation. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2006 Nov;80(2):209-10 [16645712.001]
  • [Cites] J Neurooncol. 2006 Sep;79(2):153-7 [16855865.001]
  • [Cites] Intern Med. 2007;46(8):533-4 [17443052.001]
  • [Cites] Intern Med. 2007;46(13):1029-32 [17603246.001]
  • [Cites] Clin Nucl Med. 2007 Aug;32(8):646-8 [17667443.001]
  • [Cites] Clin Nucl Med. 2008 Jan;33(1):30-1 [18097253.001]
  • [Cites] J Neurol. 2008 Jan;255(1):135-7 [17994311.001]
  • [Cites] Hematol Oncol. 2008 Mar;26(1):43-5 [17957824.001]
  • [Cites] Ophthalmology. 2008 May;115(5):e1-6 [18321583.001]
  • [Cites] Intern Med. 2008;47(12):1159-60 [18552480.001]
  • [Cites] J Neurooncol. 2008 Oct;90(1):77-83 [18592137.001]
  • [Cites] Muscle Nerve. 2008 Sep;38(3):1196-200 [18642385.001]
  • [Cites] Spine (Phila Pa 1976). 2008 Oct 1;33(21):E807-11 [18827688.001]
  • [Cites] Neurology. 2009 Jan 6;72(1):98 [19122040.001]
  • [Cites] Arch Dermatol. 2009 Mar;145(3):294-6 [19289760.001]
  • [Cites] J Neurosurg. 2009 Aug;111(2):247-51 [19216652.001]
  • [Cites] Neurology. 2001 Aug 28;57(4):740-2 [11524499.001]
  • [Cites] Neurol Sci. 2000 Aug;21(4):241-5 [11214664.001]
  • [Cites] Muscle Nerve. 2001 Aug;24(8):1068-70 [11439382.001]
  • [Cites] J Peripher Nerv Syst. 2001 Dec;6(4):197-203 [11800041.001]
  • [Cites] Ann Oncol. 2002 May;13(5):802-5 [12075752.001]
  • [Cites] Ann Nucl Med. 2002 Jun;16(4):297-8 [12126101.001]
  • [Cites] Eur J Radiol. 2002 Oct;44(1):16-8 [12350404.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):104-15 [12672282.001]
  • [Cites] Surg Neurol. 2003 Oct;60(4):343-8; discussion 348 [14505860.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2403-7 [15160344.001]
  • [Cites] Eur Neurol. 2004;52(1):57-8 [15240984.001]
  • [Cites] J Neurooncol. 2004 Jul;68(3):243-4 [15332327.001]
  • [Cites] Neurology. 1989 Jan;39(1):144-6 [2535894.001]
  • [Cites] Clin Neuropathol. 1990 Sep-Oct;9(5):224-30 [2272142.001]
  • [Cites] Neurology. 2004 Nov 9;63(9):1751 [15534276.001]
  • [Cites] Eur J Haematol. 2005 Jan;74(1):66-9 [15613109.001]
  • [Cites] J Neurooncol. 2005 Apr;72(2):163-7 [15925997.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):279-80 [15980982.001]
  • [Cites] J Neurosurg. 2005 Jun;102(6):1166 [16028783.001]
  • [Cites] J Neuroimaging. 2006 Apr;16(2):167-9 [16629741.001]
  • [Cites] Br J Neurosurg. 2006 Apr;20(2):103-5 [16753628.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Aug;33(8):975-6 [16703365.001]
  • [Cites] Neurology. 2006 Aug 22;67(4):722-3 [16924037.001]
  • [Cites] J Peripher Nerv Syst. 2007 Mar;12(1):58-60 [17374105.001]
  • (PMID = 20368468.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R13 CA124293
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3710441
  •  go-up   go-down


35. Fischer L, Martus P, Weller M, Klasen HA, Rohden B, Röth A, Storek B, Hummel M, Nägele T, Thiel E, Korfel A: Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology; 2008 Sep 30;71(14):1102-8
Zurich Open Access Repository and Archive. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients.
  • BACKGROUND: The impact of meningeal dissemination in primary CNS lymphoma (PCNSL) is debated, and the reported frequency varies.
  • CONCLUSIONS: We found a low rate of meningeal dissemination in primary CNS lymphoma in this large prospective study.
  • [MeSH-major] Lymphoma / diagnosis. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / secondary. Neoplasm Metastasis / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain / pathology. Cell Count / statistics & numerical data. Combined Modality Therapy. Cytological Techniques / statistics & numerical data. Female. Humans. Immunoglobulin Heavy Chains / analysis. Immunoglobulin Heavy Chains / blood. Magnetic Resonance Imaging / statistics & numerical data. Male. Meninges / pathology. Middle Aged. Polymerase Chain Reaction / statistics & numerical data. Predictive Value of Tests. Prospective Studies. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824675.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


36. Kramer K, Kushner BH, Modak S, Pandit-Taskar N, Smith-Jones P, Zanzonico P, Humm JL, Xu H, Wolden SL, Souweidane MM, Larson SM, Cheung NK: Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol; 2010 May;97(3):409-18
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma.
  • We evaluated the addition of compartmental intrathecal antibody-based radioimmunotherapy (cRIT) in patients with recurrent metastatic central nervous system (CNS) neuroblastoma following surgery, craniospinal irradiation, and chemotherapy.
  • Twenty one patients treated for recurrent neuroblastoma metastatic to the CNS, received a cRIT-containing salvage regimen incorporating intrathecal (131)I-monoclonal antibodies (MoAbs) targeting GD2 or B7H3 following surgery and radiation.
  • Seventeen of 21 cRIT-salvage patients are alive 7-74 months (median 33 months) since CNS relapse, with all 17 remaining free of CNS neuroblastoma.
  • This is significantly improved to published results with non-cRIT based where relapsed CNS NB has a median time to death of approximately 6 months.
  • The cRIT-salvage regimen for CNS metastases was well tolerated by young patients, despite their prior history of intensive cytotoxic therapies.
  • [MeSH-major] Central Nervous System Neoplasms / radiotherapy. Neuroblastoma / radiotherapy. Radioimmunotherapy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Drug Administration Schedule. Female. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Humans. Injections, Spinal. Male. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Time Factors. Tomography, Emission-Computed, Single-Photon / methods. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1990 Oct;62(4):637-42 [2223581.001]
  • [Cites] J Natl Cancer Inst. 1986 Sep;77(3):739-45 [3091900.001]
  • [Cites] J Nucl Med. 1992 Nov;33(11):2020-3 [1432165.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1466-77 [8336186.001]
  • [Cites] J Neurooncol. 1997 Nov;35(2):101-11 [9266446.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2202-12 [9626222.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3053-60 [9738575.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4363-7 [9766665.001]
  • [Cites] Clin Cancer Res. 1996 Jun;2(6):963-72 [9816257.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 May-Jun;21(3):181-9 [10363850.001]
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1165-73 [10519894.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jul;45(1):68-71 [15770641.001]
  • [Cites] Cancer Biother Radiopharm. 2005 Oct;20(5):534-46 [16248769.001]
  • [Cites] Bone Marrow Transplant. 2006 Feb;37(3):271-6 [16400336.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5271-6 [17114661.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5465-70 [18048828.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):182-9 [18287339.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3275s-3280s [10541375.001]
  • [Cites] Ann N Y Acad Sci. 2000 Jun;910:263-9; discussion 269-70 [10911919.001]
  • [Cites] Cancer. 2001 Apr 15;91(8):1510-9 [11301399.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4048-54 [11358824.001]
  • [Cites] Med Pediatr Oncol. 2001 Jan;36(1):194-6 [11464881.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):895-906 [12721768.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):155-65 [12833468.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Jul;25(7):515-9 [12847316.001]
  • [Cites] Eur J Cancer. 1992;28(2-3):511-3 [1591076.001]
  • (PMID = 19890606.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / FDA-KK-01A2; United States / NCI NIH HHS / CA / R21 CA117076-02; United States / NCI NIH HHS / CA / P01 CA033049-23; United States / NCI NIH HHS / CA / R21 CA089936-02; United States / FDA HHS / FD / FD003089; United States / NCI NIH HHS / CA / R21 CA089936; United States / FDA HHS / FD / R01 FD003089; United States / NCI NIH HHS / CA / P01 CA033049; United States / NCI NIH HHS / CA / CA106450; United States / NCI NIH HHS / CA / R21 CA117076; United States / NCI NIH HHS / CA / CA89935; United States / NCI NIH HHS / CA / CA117076; United States / NCI NIH HHS / CA / P01 CA106450; United States / NCI NIH HHS / CA / CA89936; United States / NCI NIH HHS / CA / R21 CA089935-02; United States / NCI NIH HHS / CA / P01 CA106450-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Other-IDs] NLM/ NIHMS250577; NLM/ PMC3533371
  •  go-up   go-down


37. Taylor AJ, Little MP, Winter DL, Sugden E, Ellison DW, Stiller CA, Stovall M, Frobisher C, Lancashire ER, Reulen RC, Hawkins MM: Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol; 2010 Dec 20;28(36):5287-93
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study.
  • PURPOSE: CNS tumors are the most common second primary neoplasm (SPN) observed after childhood cancer in Britain, but the relationship of risk to doses of previous radiotherapy and chemotherapy is uncertain.
  • Linkage to national, population-based cancer registries identified 247 SPNs of the CNS.
  • RESULTS: There were 137 meningiomas, 73 gliomas, and 37 other CNS neoplasms included in the analysis.
  • The risk of glioma/primitive neuroectodermal tumors increased linearly with dose of radiation, and those who had CNS tissue exposed to at least 40 Gy experienced a risk four-fold that experienced by those who had CNS tissue unexposed.
  • CONCLUSION: The largest-ever study, to our knowledge, of CNS tumors in survivors of childhood cancer indicates that the risk of meningioma increases rapidly with increased dose of radiation to meningeal tissue and with increased dose of intrathecal methotrexate.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21079138.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / ZIA CP010131-18; United Kingdom / Cancer Research UK / / ; United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS533866; NLM/ PMC4809645
  •  go-up   go-down


38. Yamanaka R, Morii K, Shinbo Y, Takeuchi S, Tamura T, Hondoh H, Takahashi H, Onda K, Takahashi H, Tanaka R: Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma. Ann Hematol; 2005 Jul;84(7):447-55
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
  • The object of this study was to assess the estimation of 2- and 5-year overall survival and tumor response and the frequency and severity of treatment morbidity with a modified ProMACE-MOPP hybrid protocol in patients with primary CNS lymphoma (PCNSL).
  • Eighteen patients were followed up with neuroimaging and neuropsychological assessments for evidence of CNS toxicity.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Central Nervous System Neoplasms / therapy. Cranial Irradiation. Lymphoma / therapy. Methotrexate / administration & dosage
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / toxicity. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / toxicity. Etoposide / administration & dosage. Etoposide / toxicity. Female. Humans. Leukopenia / chemically induced. Male. Mechlorethamine / administration & dosage. Mechlorethamine / toxicity. Middle Aged. Pneumonia / etiology. Pneumonia / mortality. Prednisone / administration & dosage. Prednisone / toxicity. Procarbazine / administration & dosage. Procarbazine / toxicity. Retrospective Studies. Sepsis / etiology. Sepsis / mortality. Vincristine / administration & dosage. Vincristine / toxicity

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15747120.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ProMACE-MOPP protocol
  •  go-up   go-down


39. Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T, Muzikansky A, Hochberg EP: Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer; 2010 Sep 15;116(18):4283-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
  • Unfortunately, approximately 5% of these patients still developed a secondary central nervous system (CNS) recurrence followed invariably by rapid death.
  • Although prophylaxis against CNS recurrence with either intrathecal or intravenous methotrexate is commonly used for such patients, to the authors' knowledge, there is no standard of care.
  • Retrospectively evaluated was the role of high-dose systemic methotrexate combined with standard cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab (R-CHOP) chemotherapy to decrease CNS recurrence in high-risk patients.
  • METHODS: A total of 65 patients with DLBCL and CNS risk factors were identified at the study institution between 2000 and 2008 who received intravenous methotrexate as CNS prophylaxis concurrent with standard systemic therapy with curative intent.
  • CNS recurrence rate, progression-free survival, and overall survival were calculated.
  • At a median follow-up of 33 months, there were only 2 CNS recurrences (3%) in this high-risk population.
  • CONCLUSIONS: Intravenous methotrexate can be safely administered concurrently with R-CHOP and is associated with a low risk of CNS recurrence in high-risk patients.
  • [MeSH-major] Central Nervous System Neoplasms / prevention & control. Central Nervous System Neoplasms / secondary. Lymphoma, Large B-Cell, Diffuse / drug therapy. Methotrexate / administration & dosage
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / analysis. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / analysis. Doxorubicin / therapeutic use. Drug Administration Schedule. Female. Humans. Injections, Intravenous. Male. Middle Aged. Prednisone / analysis. Prednisone / therapeutic use. Recurrence. Risk. Rituximab. Vincristine / analysis. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Cancer Society.
  • [CommentIn] Cancer. 2011 Jun 1;117(11):2579-80; author reply 2580-1 [24048807.001]
  • (PMID = 20564149.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol
  •  go-up   go-down


40. Kiewe P, Loddenkemper C, Anagnostopoulos I, Reinwald M, Thiel E, Korfel A: High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma. Neuro Oncol; 2007 Apr;9(2):96-102
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma.
  • In patients with parenchymal brain masses of uncertain origin responsive to corticosteroids, primary CNS lymphoma (PCNSL) should be considered.
  • PCNSL is a rare but aggressive brain tumor that is highly sensitive to high-dose methotrexate (HDMTX)-based chemotherapy.
  • [MeSH-major] Brain Neoplasms / drug therapy. Central Nervous System Neoplasms / drug therapy. Lymphoma / drug therapy. Methotrexate / therapeutic use
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / therapeutic use. Biopsy. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Recurrence. Stereotaxic Techniques

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1999 Jul;43(3):231-6 [10563428.001]
  • [Cites] Clin Imaging. 2004 Jul-Aug;28(4):261-70 [15246475.001]
  • [Cites] Eur J Endocrinol. 2000 Apr;142(4):365-72 [10754478.001]
  • [Cites] Mol Pathol. 2000 Aug;53(4):194-200 [11040942.001]
  • [Cites] J R Soc Med. 2000 Nov;93(11):586-8 [11198690.001]
  • [Cites] Neurology. 2001 May 22;56(10):1313-8 [11376180.001]
  • [Cites] J Neurol. 2001 Jun;248(6):451-68 [11499635.001]
  • [Cites] Neurology. 2001 Aug 14;57(3):393-6 [11515505.001]
  • [Cites] Neurology. 2002 Feb 12;58(3):390-6 [11839837.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):354-62 [12186464.001]
  • [Cites] Neurology. 2002 Sep 10;59(5):762-4 [12221174.001]
  • [Cites] Neurology. 1988 Jul;38(7):1153-5 [3386836.001]
  • [Cites] Cancer. 1988 Dec 1;62(11):2461-5 [3179963.001]
  • [Cites] AJNR Am J Neuroradiol. 1989 Jul-Aug;10(4):725-9 [2505501.001]
  • [Cites] Br J Neurosurg. 1990;4(5):407-15 [2261103.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):9-17 [1572835.001]
  • [Cites] AJNR Am J Neuroradiol. 1992 Jul-Aug;13(4):1207-13 [1636538.001]
  • [Cites] J Nucl Med. 1993 Apr;34(4):567-75 [8455072.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):188-95 [8027800.001]
  • [Cites] Oncology (Williston Park). 1995 Jan;9(1):63-71; discussion 71, 75-6, 78 [7718442.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1996 Jan;60(1):102-5 [8558135.001]
  • [Cites] Ophthalmology. 1996 Mar;103(3):521-8 [8600431.001]
  • [Cites] Clin Imaging. 1996 Jul-Sep;20(3):171-7 [8877168.001]
  • [Cites] Neuroradiology. 1996 Aug;38(6):560-5 [8880719.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):859-63 [9508166.001]
  • [Cites] Cancer. 1998 May 1;82(9):1749-55 [9576298.001]
  • [Cites] J Neurol Sci. 2004 Dec 15;227(1):85-9 [15546596.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):173-80 [15690135.001]
  • [Cites] Br J Haematol. 2005 Mar;128(5):616-24 [15725082.001]
  • [Cites] Neurol Sci. 2004 Nov;25 Suppl 4:S361-3 [15727234.001]
  • [Cites] J Neurooncol. 2005 Apr;72(2):169-77 [15925998.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • [Cites] QJM. 2005 Sep;98(9):643-54 [16040668.001]
  • [Cites] Neurology. 2005 Oct 11;65(7):1057-65 [16217059.001]
  • [Cites] Arch Neurol. 2005 Nov;62(11):1673-80 [16286539.001]
  • [Cites] Clin Neurol Neurosurg. 2007 Jan;109(1):92-101 [16644103.001]
  • [Cites] Neurosci Lett. 2003 Feb 27;338(2):119-22 [12566167.001]
  • [Cites] Neurosci Lett. 2003 May 22;342(3):163-6 [12757890.001]
  • [Cites] Br J Radiol. 2004 Feb;77(914):153-6 [15010391.001]
  • [Cites] Arq Neuropsiquiatr. 1999 Dec;57(4):921-6 [10683680.001]
  • (PMID = 17301290.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC1871672
  •  go-up   go-down


41. Lollis SS, Roberts DW: Robotic placement of a CNS ventricular reservoir for administration of chemotherapy. Br J Neurosurg; 2009;23(5):516-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic placement of a CNS ventricular reservoir for administration of chemotherapy.
  • We hypothesized that image-guided, robotic placement of a CNS ventriculostomy reservoir for intraventricular chemotherapy is safe, highly accurate, and highly reproducible.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Central Nervous System Neoplasms / drug therapy. Robotics. Ventriculostomy / instrumentation
  • [MeSH-minor] Adult. Aged. Catheterization / instrumentation. Catheterization / methods. Drug Implants. Equipment Design. Female. Humans. Male. Middle Aged. Retrospective Studies. Stereotaxic Techniques / instrumentation. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19669983.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Implants
  •  go-up   go-down


42. Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Kawai N, Satoh K, Ohkawa M: Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma. Eur J Nucl Med Mol Imaging; 2007 Jan;34(1):78-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma.
  • PURPOSE: The purpose of this study was to investigate the accumulation of FDG in immunocompetent patients with primary central nervous system (CNS) lymphoma using qualitative and quantitative PET images and to compare baseline with follow-up PET after therapy.
  • METHODS: Twelve immunocompetent patients with CNS lymphoma were examined.
  • RESULTS: A total of 12 lesions were identified in ten patients with newly diagnosed CNS lymphoma.
  • CONCLUSION: Kinetic analysis, especially with respect to k (3), using dynamic FDG PET might be helpful for diagnosis of CNS lymphoma and for monitoring therapeutic assessment.
  • [MeSH-major] Brain Neoplasms / diagnostic imaging. Brain Neoplasms / metabolism. Fluorodeoxyglucose F18 / pharmacokinetics. Image Interpretation, Computer-Assisted / methods. Lymphoma / diagnosis. Lymphoma / metabolism
  • [MeSH-minor] Adult. Computer Simulation. Female. Humans. Immunocompetence / immunology. Kinetics. Male. Middle Aged. Models, Biological. Positron-Emission Tomography / methods. Radiopharmaceuticals / pharmacokinetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurol Med Chir (Tokyo). 1990 Jun;30(6):377-81 [1700316.001]
  • [Cites] J Nucl Med. 2002 Apr;43(4):500-9 [11937594.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Feb;33(2):164-8 [16220304.001]
  • [Cites] J Neurosurg. 1988 Jun;68(6):835-53 [3286832.001]
  • [Cites] J Nucl Med. 1993 Apr;34(4):567-75 [8455072.001]
  • [Cites] Lancet. 2003 Jan 25;361(9354):323-31 [12559880.001]
  • [Cites] FEBS Lett. 1987 May 25;216(1):128-32 [3582661.001]
  • [Cites] J Clin Oncol. 1993 Nov;11(11):2101-11 [8229124.001]
  • [Cites] J Neurooncol. 1992 Feb;12 (2):159-65 [1560262.001]
  • [Cites] J Cereb Blood Flow Metab. 1985 Jun;5(2):163-78 [3872872.001]
  • [Cites] J Neurochem. 1977 May;28(5):897-916 [864466.001]
  • [Cites] Radiographics. 1994 Jan;14 (1):101-10 [8128041.001]
  • [Cites] Neurology. 1982 Dec;32(12 ):1323-9 [6983044.001]
  • [Cites] Radiology. 1988 Mar;166(3):823-7 [2829270.001]
  • [Cites] Clin Positron Imaging. 1998 Dec;1(1):15-30 [14516605.001]
  • [Cites] Radiology. 1995 Oct;197(1):221-6 [7568827.001]
  • [Cites] Radiology. 1994 Jan;190(1):111-6 [8259386.001]
  • [Cites] J Neurosurg. 1986 Nov;65(5):592-9 [3772444.001]
  • [Cites] Neuroradiology. 1996 Jan;38(1):34-7 [8773272.001]
  • [Cites] Nucl Med Biol. 2002 May;29(4):443-53 [12031879.001]
  • [Cites] J Nucl Med. 1991 Aug;32(8):1485-90 [1714497.001]
  • [Cites] J Nucl Med. 1992 Apr;33(4):532-6 [1552337.001]
  • [Cites] Cancer. 1994 May 1;73(9):2386-94 [8168042.001]
  • [Cites] J Nucl Med. 1997 Sep;38(9):1384-6 [9293793.001]
  • [Cites] J Nucl Med. 1997 Jul;38(7):1027-9 [9225785.001]
  • [Cites] J Nucl Med. 2004 Sep;45(9):1528-35 [15347720.001]
  • [Cites] Blood. 1998 Jun 15;91(12 ):4464-71 [9616140.001]
  • [Cites] Mol Imaging Biol. 2003 Jan-Feb;5(1):32-41 [14499160.001]
  • [Cites] J Nucl Med. 1997 Oct;38(10 ):1575-83 [9379195.001]
  • [Cites] Eur J Nucl Med. 1998 Sep;25(9):1261-9 [9724375.001]
  • [Cites] Ann Neurol. 1979 Nov;6(5):371-88 [117743.001]
  • [Cites] Eur J Cancer. 2002 Jul;38(10):1298-312 [12091059.001]
  • [Cites] Cancer. 1988 Sep 15;62(6):1074-8 [3261622.001]
  • (PMID = 16896670.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


43. Portera CC, Gottesman RF, Srodon M, Asrari F, Dillon M, Armstrong DK: Optic neuropathy from metastatic squamous cell carcinoma of the cervix: an unusual CNS presentation. Gynecol Oncol; 2006 Jul;102(1):121-3
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optic neuropathy from metastatic squamous cell carcinoma of the cervix: an unusual CNS presentation.
  • BACKGROUND: Central nervous system (CNS) metastases from cervical carcinoma are uncommon events.
  • No measurable disease was evident outside of the CNS.
  • Rapid progression of this patient's CNS metastatic disease suggests this form of metastases may be more aggressive and carry extremely poor prognosis.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Optic Nerve Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16507318.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Grimm SA, McCannel CA, Omuro AM, Ferreri AJ, Blay JY, Neuwelt EA, Siegal T, Batchelor T, Jahnke K, Shenkier TN, Hall AJ, Graus F, Herrlinger U, Schiff D, Raizer J, Rubenstein J, Laperriere N, Thiel E, Doolittle N, Iwamoto FM, Abrey LE: Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology; 2008 Oct 21;71(17):1355-60
HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report.
  • OBJECTIVE: To describe the demographics, diagnostic details, therapeutic management, and outcome in patients with primary CNS lymphoma (PCNSL) with ocular involvement.
  • CONCLUSION: This is the largest reported series of primary CNS lymphoma (PCNSL) with intraocular involvement.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. Cooperative Behavior. Eye Neoplasms / epidemiology. Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Internationality. Male. Middle Aged. Research / trends. Retrospective Studies. Survival Rate / trends

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):742-9 [11157026.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4643-8 [12488408.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):31-5 [9647169.001]
  • [Cites] Ocul Immunol Inflamm. 2006 Jun;14(3):139-44 [16827214.001]
  • [Cites] Semin Ophthalmol. 2006 Jul-Sep;21(3):125-33 [16912010.001]
  • [Cites] Leuk Lymphoma. 2006 Sep;47(9):1800-5 [17064991.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5711-5 [17116938.001]
  • [Cites] Ann Oncol. 2007 Nov;18(11):1851-5 [17804469.001]
  • [Cites] Br J Ophthalmol. 2008 Mar;92(3):383-8 [18303160.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):711-5 [12576439.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1044-9 [12637469.001]
  • [Cites] Cancer Control. 2004 Sep-Oct;11(5):285-95 [15377987.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):635-43 [1548527.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):165-8 [8027795.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):188-95 [8027800.001]
  • [Cites] Ann Neurol. 1995 Aug;38(2):202-9 [7654067.001]
  • [Cites] Oncology. 2001;60(2):134-40 [11244328.001]
  • (PMID = 18936428.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA100291; United States / NCI NIH HHS / CA / R13 CA124293
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC4109164
  •  go-up   go-down


45. Fischer L, Korfel A, Kiewe P, Neumann M, Jahnke K, Thiel E: Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma. Ann Hematol; 2009 Feb;88(2):133-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma.
  • Patients with malignant central nervous system (CNS) involvement of lymphoma have a poor prognosis with intrathecal chemotherapy and radiation.
  • The study involved a review of all patients who received HDMTX/IFO for CNS involvement of malignant lymphoma at our hospital.
  • The study included 20 patients with a median age of 65 years (range, 30-83) and CNS relapse of a malignant lymphoma.
  • Systemic chemotherapy with HDMTX/IFO is a feasible and promising treatment modality for CNS relapse of a malignant lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Ifosfamide / therapeutic use. Lymphoma / drug therapy. Methotrexate / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679681.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


46. Trivin C, Couto-Silva AC, Sainte-Rose C, Chemaitilly W, Kalifa C, Doz F, Zerah M, Brauner R: Presentation and evolution of organic central precocious puberty according to the type of CNS lesion. Clin Endocrinol (Oxf); 2006 Aug;65(2):239-45
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presentation and evolution of organic central precocious puberty according to the type of CNS lesion.
  • OBJECTIVE: To evaluate the influence of the type and treatment of CNS lesion causing central precocious puberty (CPP) on the presentation, hypothalamic-pituitary function and final height.
  • PATIENTS: One hundred patients with CPP caused by central nervous system (CNS) lesion.
  • CONCLUSIONS: The type of CNS lesion influences the presentation of CPP.
  • [MeSH-major] Brain Neoplasms / complications. Hypothalamic Diseases / etiology. Pituitary Diseases / etiology. Puberty, Precocious / etiology
  • [MeSH-minor] Adolescent. Adult. Arachnoid Cysts / blood. Arachnoid Cysts / complications. Astrocytoma / blood. Astrocytoma / complications. Body Height. Child. Child, Preschool. Female. Follicle Stimulating Hormone / blood. Gonadal Steroid Hormones / blood. Growth Hormone / blood. Growth Hormone-Releasing Hormone. Hamartoma / blood. Hamartoma / complications. Humans. Hydrocephalus / blood. Hydrocephalus / complications. Hydrocortisone / blood. Hypothalamic Neoplasms / blood. Hypothalamic Neoplasms / complications. Luteinizing Hormone / blood. Male. Meningomyelocele / blood. Meningomyelocele / complications. Optic Nerve Glioma / blood. Optic Nerve Glioma / complications. Statistics, Nonparametric


47. Santosh V, Mahadevan A, Chickabasaviah YT, Bharath RD, Krishna SS: Infectious lesions mimicking central nervous system neoplasms. Semin Diagn Pathol; 2010 May;27(2):122-35
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infectious lesions mimicking central nervous system neoplasms.
  • Infections of the central nervous system (CNS) presenting as space-occupying lesions are not uncommon, particularly in developing countries.
  • Most often, infective organisms gain entry into the CNS through the hematogenous route, seed the parenchyma, and cause tissue destruction.
  • Although neoplasms are the common considerations in the presence of enhancing lesions with perilesional edema and mass effect on neuroimaging, nonneoplastic conditions-in particular, infectious lesions--can have similar imaging characteristics.
  • Biopsy diagnosis is mandatory for neoplasms, both for confirmation of diagnosis as well as grading, but most infectious lesions are managed conservatively if the diagnosis is established by noninvasive means.
  • This review discusses some of the common infectious lesions that mimic CNS neoplasms, with emphasis on pyogenic, tuberculous, and fungal lesions as well as parasitic and viral infections that present as intracranial space-occupying lesions.
  • The data of infective lesions that mimicked intracranial neoplasms, from our institute, over the last 5 years, are also presented.
  • [MeSH-major] Brain Neoplasms / diagnosis. Central Nervous System Infections / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20860316.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


48. Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM: Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol; 2008 Jul;19(7):1242-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defining prognosis for women with breast cancer and CNS metastases by HER2 status.
  • BACKGROUND: The purpose of this retrospective study was to determine, in a cohort of patients with breast cancer and central nervous system (CNS) metastases, the effect of trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive disease and to compare this with that of patients with HER2-negative disease.
  • METHODS: Five hundred and ninety-eight patients with invasive breast cancer, CNS metastases and known HER2 status were identified.
  • Time to CNS metastases and survival after CNS metastases were estimated by the Kaplan-Meier method, and Cox models were fitted to determine the association between HER2 status, trastuzumab treatment and outcomes after adjustment for other patient characteristics.
  • RESULTS: In the multivariable model, patients with HER2-negative disease [Hazard ratio (HR) 1.50, 95% confidence interval (CI) 1.15-1.95, P = 0.003] and patients with HER2-positive disease who did not receive trastuzumab (HR 2.13, 95% CI 1.51-3.00, P < 0.0001) had shorter times to CNS metastases compared with patients with HER2-positive disease who had received trastuzumab as first-line therapy for metastases.
  • Furthermore, patients with HER2-negative disease (HR 1.66, 95% CI 1.31-2.12, P < 0.0001) and patients with HER2-positive disease who had never received trastuzumab (HR 1.34, 95% CI 0.78-2.30, P = 0.28) had an increased hazard of death compared with patients with HER2-positive disease who had received trastuzumab before or at the time of CNS metastases diagnosis.
  • CONCLUSION: In our cohort of patients with breast cancer and CNS metastases, patients with HER2-positive disease treated with trastuzumab had longer times to development of and better survival from CNS metastases compared with patients with HER2-positive disease who had never received trastuzumab and patients with HER2-negative breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18334512.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23CA121994-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


49. Shah AC, Kelly DR, Nabors LB, Oakes WJ, Hilliard LM, Reddy AT: Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent pediatric patients. Pediatr Blood Cancer; 2010 Dec 1;55(6):1227-30
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent pediatric patients.
  • We report two cases of primary CNS lymphoma (PCNSL) treated with high-dose methotrexate.
  • Though standard adult treatment of PCNSL incorporates whole-brain radiotherapy, the literature suggests it may be possible to delay or avoid radiotherapy and the associated increased risk of neurologic sequelae in pediatric patients.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Central Nervous System Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Large-Cell, Anaplastic / drug therapy. Methotrexate / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Blood Cancer. 2011 Jul 1;56(7):1151 [21312324.001]
  • (PMID = 20882580.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


50. Shenkier TN, Blay JY, O'Neill BP, Poortmans P, Thiel E, Jahnke K, Abrey LE, Neuwelt E, Tsang R, Batchelor T, Harris N, Ferreri AJ, Ponzoni M, O'Brien P, Rubenstein J, Connors JM: Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol; 2005 Apr 1;23(10):2233-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group.
  • PURPOSE: To describe the demographic and tumor related characteristics and outcomes for patients with primary T-cell CNS lymphoma (TPCNSL).
  • Univariate and multivariate analyses were conducted for age (</= 60 v > 60 years), PS (0 or 1 v 2, 3, or 4), involvement of deep structures of the CNS (no v yes), and methotrexate (MTX) use in the primary treatment (yes v no).
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Child. Child, Preschool. Cohort Studies. Female. Health Status. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Multivariate Analysis. Prognosis. Retrospective Studies. Survival Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800313.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


51. Schmidt K, Schulz AS, Debatin KM, Friedrich W, Classen CF: CNS complications in children receiving chemotherapy or hematopoietic stem cell transplantation: retrospective analysis and clinical study of survivors. Pediatr Blood Cancer; 2008 Feb;50(2):331-6
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS complications in children receiving chemotherapy or hematopoietic stem cell transplantation: retrospective analysis and clinical study of survivors.
  • BACKGROUND: Clinical studies analyzing CNS complications in pediatric oncology systematically are rare.
  • PROCEDURE: In a single center retrospective analysis, CNS complications in 950 subsequent pediatric patients treated between 1992 and 2004 by chemotherapy or hematopoietic stem cell transplantation (HSCT) were studied.
  • Forty-six patients had pre-existing CNS diseases and were excluded.
  • Out of the 904 remaining, 76 (8.4%) had 82 CNS complications.
  • RESULTS: The most common manifestations were seizures (in 50.6% of the CNS episodes), altered states of consciousness, and motor deficits (in 47.5% of the episodes each).
  • CNS complications were caused by infections (26.8%), toxicity (25.6%), neoplasma (13.4%), vascular (10.9%), and metabolic disturbances (8.5%).
  • Patients (23.7%) died from the CNS event.
  • CONCLUSIONS: These data show that there is not one typical CNS complication, but a wide variety.
  • [MeSH-major] Central Nervous System Diseases / etiology. Hematologic Diseases / therapy. Hematopoietic Stem Cell Transplantation / adverse effects. Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17455315.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Chi SN, Zimmerman MA, Yao X, Cohen KJ, Burger P, Biegel JA, Rorke-Adams LB, Fisher MJ, Janss A, Mazewski C, Goldman S, Manley PE, Bowers DC, Bendel A, Rubin J, Turner CD, Marcus KJ, Goumnerova L, Ullrich NJ, Kieran MW: Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol; 2009 Jan 20;27(3):385-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor.
  • PURPOSE: Atypical teratoid rhabdoid tumor (ATRT) of the CNS is a highly malignant neoplasm primarily affecting young children, with a historic median survival ranging from 6 to 11 months.
  • Based on a previous pilot series, a prospective multi-institutional trial was conducted for patients with newly diagnosed CNS ATRT.
  • Gross total resection of the primary tumor was achieved in 11 patients.
  • CONCLUSION: This intensive multimodality regimen has resulted in a significant improvement in time to progression and overall survival for patients with this previously poor-prognosis tumor.
  • [MeSH-major] Brain Neoplasms / therapy. Rhabdoid Tumor / therapy. Teratoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Humans. Infratentorial Neoplasms. Prognosis. Prospective Studies. Supratentorial Neoplasms. Young Adult

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):337-42 [12142780.001]
  • [Cites] Pediatr Blood Cancer. 2008 Aug;51(2):235-40 [18381756.001]
  • [Cites] Radiology. 1969 Dec;93(6):1351-9 [4983156.001]
  • [Cites] Hum Pathol. 1987 Apr;18(4):332-7 [3030922.001]
  • [Cites] Pediatr Neurol. 1991 Jul-Aug;7(4):237-42 [1930413.001]
  • [Cites] Med Pediatr Oncol. 1992;20(3):258 [1637409.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):71-5 [7743242.001]
  • [Cites] J Neurooncol. 1995;24(1):21-8 [8523069.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1013-9 [9719110.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1083-92 [9737241.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1491-9 [15735125.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):978-86 [15758008.001]
  • [Cites] J Neurooncol. 2005 Mar;72(1):77-84 [15803379.001]
  • [Cites] Pediatr Blood Cancer. 2005 May;44(5):478-86 [15918215.001]
  • [Cites] Neurosurg Focus. 2005 Jun 15;18(6A):E8 [16048294.001]
  • [Cites] J Neurooncol. 2007 Jan;81(1):97-111 [16855864.001]
  • [Cites] J Pediatr Psychol. 2007 Sep;32(8):918-25 [17522113.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):928-40 [17066459.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2877-84 [15254056.001]
  • (PMID = 19064966.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA046274; United States / NCI NIH HHS / CA / R01 CA046274-17A2; United States / NCI NIH HHS / CA / CA46274
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2645855
  •  go-up   go-down


53. Tu PH, Giannini C, Judkins AR, Schwalb JM, Burack R, O'Neill BP, Yachnis AT, Burger PC, Scheithauer BW, Perry A: Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma. J Clin Oncol; 2005 Aug 20;23(24):5718-27
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma.
  • PURPOSE: Although rare overall, marginal zone B-cell lymphoma (MZBCL) is the most common primary low-grade CNS lymphoma reported in the literature.
  • The aim of this study is to elucidate the biology and genetic features of this unusual tumor.
  • PATIENTS AND METHODS: Fifteen CNS MZBCLs were studied clinically, pathologically, and genetically, including fluorescent in situ hybridization analyses with commercially available MALT1 and IgH break-apart and centromere 3, 7, 12, and 18 probes.
  • RESULTS: CNS MZBCLs preferentially affect middle-aged women (female-to-male ratio, 4:1), with 93% presenting as dural-based masses mimicking meningioma.
  • Like MZBCLs outside of the CNS, they consisted of CD20+, CD3- small B lymphocytes with varying degrees of plasmacytic differentiation and predominantly kappa light-chain restriction (78%).
  • CONCLUSION: Our data suggest that intracranial MZBCL is an indolent primary CNS lymphoma that typically presents as a meningioma-like dural-based mass.
  • Trisomy 3, but not MALT1 or IgH translocation, is a common genetic abnormality that may contribute to the pathogenesis of this CNS lymphoma.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Central Nervous System Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, B-Cell, Marginal Zone / pathology
  • [MeSH-minor] Adult. Aged. Chromosomes, Human, Pair 3. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Meningioma / pathology. Middle Aged. Translocation, Genetic. Trisomy

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16009945.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Neuwelt EA, Guastadisegni PE, Várallyay P, Doolittle ND: Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. AJNR Am J Neuroradiol; 2005 Feb;26(2):258-65
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery.
  • We hypothesized that this would also be true in primary CNS lymphoma (PCNSL) patients who attained a complete response (CR) after treatment with chemotherapy and osmotic blood-brain barrier disruption (BBBD).
  • We hypothesized that cognitive function loss measured after tissue diagnosis but before BBBD-enhanced chemotherapy could be correlated with brain changes visualized by imaging, whereas a correlation would not be present after therapy if the patient attained a complete tumor response, analogous to the findings in children.
  • METHODS: Sixteen primary CNS lymphoma patients were followed after CR (no enhancing tumor) by using a methotrexate-based regimen.
  • Zone I was defined as enhancing tumor, and zone II as surrounding abnormal MR T2 signal intensity or low-attenuation CT.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / diagnosis. Brain Neoplasms / drug therapy. Cognition / drug effects. Lymphoma / diagnosis. Lymphoma / drug therapy. Magnetic Resonance Imaging. Methotrexate / administration & dosage. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Blood-Brain Barrier. Child. Female. Humans. Male. Middle Aged. Neuropsychological Tests. Remission Induction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] AJNR Am J Neuroradiol. 2005 Feb;26(2):205-6 [15709113.001]
  • (PMID = 15709122.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS 33618; United States / NINDS NIH HHS / NS / NS 34608; United States / NINDS NIH HHS / NS / R01 NS 44687
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


55. Syczewska M, Dembowska-Bagińska B, Perek-Polnik M, Kalinowska M, Perek D: Gait pathology assessed with Gillette Gait Index in patients after CNS tumour treatment. Gait Posture; 2010 Jul;32(3):358-62
MedlinePlus Health Information. consumer health - Walking Problems.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gait pathology assessed with Gillette Gait Index in patients after CNS tumour treatment.
  • This study evaluated the gait pathology of the patients after the combined treatment for central nervous system (CNS) tumours.
  • Gait analysis was undertaken using VICON 460 movement analysis system.
  • [MeSH-major] Brain Neoplasms / diagnosis. Gait / physiology. Gait Disorders, Neurologic / diagnosis
  • [MeSH-minor] Adolescent. Age Factors. Analysis of Variance. Case-Control Studies. Central Nervous System Neoplasms / complications. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / therapy. Child. Child, Preschool. Female. Follow-Up Studies. Health Status Indicators. Humans. Male. Reference Values. Risk Assessment. Severity of Illness Index. Sex Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20630761.001).
  • [ISSN] 1879-2219
  • [Journal-full-title] Gait & posture
  • [ISO-abbreviation] Gait Posture
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


56. Ekstein D, Ben-Yehuda D, Slyusarevsky E, Lossos A, Linetsky E, Siegal T: CSF analysis of IgH gene rearrangement in CNS lymphoma: relationship to the disease course. J Neurol Sci; 2006 Aug 15;247(1):39-46
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CSF analysis of IgH gene rearrangement in CNS lymphoma: relationship to the disease course.
  • PURPOSE: To assess whether clonal IgH genes in CSF of patients with CNS lymphoma correlates with the disease course.
  • METHODS: Seventy-three CSF specimens from 32 patients (27 with primary CNS lymphoma and 5 with an isolated parenchymal CNS relapse of systemic lymphoma) were examined.
  • CNS disease was defined as active when leptomeningeal and/or parenchymal brain involvement was evident on neuroimaging.
  • Patients were considered to have a complete response when imaging confirmed absence of a tumor mass or leptomeningeal seeding.
  • The PCR study has high specificity and positive results are indicative for the presence of active disease, even when the tumor seems confined to the brain parenchyma.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Gene Rearrangement. Immunoglobulin Heavy Chains / cerebrospinal fluid. Immunoglobulin Heavy Chains / genetics. Lymphoma / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. False Negative Reactions. False Positive Reactions. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. Reproducibility of Results. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16678210.001).
  • [ISSN] 0022-510X
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


57. Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V, Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire: Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol; 2008 May 20;26(15):2512-8
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
  • PURPOSE: The prognosis of relapsing primary CNS lymphoma (PCNSL) is poor.
  • We report the results of a prospective multicenter trial of intensive chemotherapy followed by autologous hematopoietic stem-cell rescue (IC + HCR) in immunocompetent adult patients with PCNSL or intraocular lymphoma (IOL) after failure of high-dose methotrexate-based treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Eye Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Lymphoma, Large B-Cell, Diffuse / therapy. Neoplasm Recurrence, Local / therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Busulfan / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Prospective Studies. Survival Rate. Thiotepa / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18413641.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; 905Z5W3GKH / Thiotepa; G1LN9045DK / Busulfan
  •  go-up   go-down


58. Santagata S, Hornick JL, Ligon KL: Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG. Am J Surg Pathol; 2006 Dec;30(12):1613-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG.
  • Expression of NANOG has been detected in fetal germ cells and in gonadal germ cell tumors.
  • To assess the diagnostic utility of NANOG in central nervous system (CNS) germ cell tumors, we analyzed its expression by immunohistochemistry in a series of 12 CNS germinomas and compared its expression with other stem cell markers.
  • Strong nuclear expression of NANOG was demonstrated in >90% of the tumor cells in all cases.
  • NANOG was not detected in tumor types frequently considered in the differential diagnosis of CNS germinoma: pineoblastoma, primitive neuroectodermal tumors, medulloblastoma, lymphoma, pituitary adenoma, atypical teratoid/rhabdoid tumor, Langerhans cell histiocytosis, and gliomas.
  • These findings demonstrate that NANOG is a sensitive and specific marker of CNS germinoma.
  • Compared with other currently used markers, NANOG may have superior diagnostic characteristics and can facilitate identification of germinomas in minute surgical biopsies commonly obtained from these tumors.
  • These findings also suggest a potential biologic role for NANOG in maintenance of CNS germinoma.
  • [MeSH-major] Brain Neoplasms / metabolism. DNA-Binding Proteins / metabolism. Germinoma / metabolism. Homeodomain Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Alkaline Phosphatase / metabolism. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Child. HMGB Proteins / metabolism. Humans. Isoenzymes / metabolism. Octamer Transcription Factor-3 / metabolism. SOXB1 Transcription Factors. Transcription Factors / metabolism

  • Genetic Alliance. consumer health - Germinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122519.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS047213
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / HMGB Proteins; 0 / Homeodomain Proteins; 0 / Isoenzymes; 0 / NANOG protein, human; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors; 0 / Transcription Factors; 0 / germ-cell AP isoenzyme; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


59. Doolittle ND, Jahnke K, Belanger R, Ryan DA, Nance RW Jr, Lacy CA, Tyson RM, Haluska M, Hedrick NA, Varallyay C, Neuwelt EA: Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma. Leuk Lymphoma; 2007 Sep;48(9):1712-20
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma.
  • There was good uptake of Indium-111 ibritumomab tiuxetan in tumor on SPECT scan after 48 h.
  • Estimated radiation doses to brain around and distant from tumor were within safe limits.
  • After Ytrium-90 ibritumomab tiuxetan there was CR in enhancing tumor where the BBB was leaky, but lesions occurred in other brain regions, where the BBB was intact during Yttrium-90 ibritumomab tiuxetan infusion.
  • Imaging and dosimetry with Indium-111 ibritumomab tiuxetan and efficacy with Yttrium-90 ibritumomab tiuxetan suggest the need for future enhanced CNS delivery when using monoclonal or radiolabeled antibodies, as intravenous delivery alone may provide modest clinical benefit due to limited BBB permeability.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / therapy. Lymphoma, Non-Hodgkin / therapy. Radioimmunotherapy. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adult. Aged. Blood-Brain Barrier. Carboplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Indium Radioisotopes / therapeutic use. Male. Methotrexate / administration & dosage. Middle Aged

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786706.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS33618; United States / NINDS NIH HHS / NS / NS34608; United States / NINDS NIH HHS / NS / NS44687
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Indium Radioisotopes; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan; BG3F62OND5 / Carboplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


60. Jahnke K, Hummel M, Korfel A, Burmeister T, Kiewe P, Klasen HA, Müller HH, Stein H, Thiel E: Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. J Clin Oncol; 2006 Oct 10;24(29):4754-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes.
  • PURPOSE: To search for subclinical systemic disease in bone marrow and peripheral blood in patients with primary CNS lymphoma (PCNSL) to elucidate whether extracerebral relapse may represent a sequel of initial occult systemic disease rather than true extracerebral spread.
  • RESULTS: Identical dominant PCR products were found in bone marrow aspirates, blood samples, and tumor biopsy specimens of two patients, indicating that the same tumor cell population is present in the CNS and in extracerebral sites.
  • An oligoclonal IgH rearrangement pattern was found in the tumor specimen of two other patients, whereas bone marrow and blood samples demonstrated the same dominant PCR products.
  • [MeSH-major] Bone Marrow Neoplasms / diagnosis. Brain Neoplasms / diagnosis. Immunoglobulin Heavy Chains / genetics. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow / chemistry. Female. Gene Rearrangement. Humans. Male. Middle Aged. Neoplasm Staging / methods. Polymerase Chain Reaction. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966685.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


61. Kästner F, Paulus W, Deckert M, Schlegel P, Evers S, Husstedt IW: [Primary CNS lymphoma in azathioprine therapy for autoimmune diseases: review of the literature and case report]. Nervenarzt; 2007 Apr;78(4):451-6
Hazardous Substances Data Bank. AZATHIOPRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary CNS lymphoma in azathioprine therapy for autoimmune diseases: review of the literature and case report].
  • We present a 31-year-old female patient with primary non-Hodgkin's lymphoma of the CNS after immunosuppressive therapy.
  • The risk of primary CNS lymphoma under azathioprine treatment for an autoimmune disease with a possible congenital immunodeficiency is presented and the literature is reviewed.
  • [MeSH-major] Autoimmune Diseases / drug therapy. Azathioprine / adverse effects. Brain Neoplasms / chemically induced. Brain Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / chemically induced. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Colitis, Ulcerative / complications. Colitis, Ulcerative / drug therapy. Female. Humans. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use

  • Genetic Alliance. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1996 Jan 27;347(8996):215-9 [8551879.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):72-7 [11781282.001]
  • [Cites] Lancet. 1994 May 21;343(8908):1249-52 [7910274.001]
  • [Cites] Gut. 2005 Aug;54(8):1121-5 [16009685.001]
  • [Cites] Gastroenterology. 2001 Nov;121(5):1080-7 [11677199.001]
  • [Cites] Nervenarzt. 2004 Dec;75(12):1217-21 [15224176.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):199-201 [10563423.001]
  • [Cites] J Neurosurg. 1978 Dec;49(6):887-92 [366088.001]
  • [Cites] Neurology. 1988 Feb;38(2):258-61 [3340289.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Sep;2(9):731-43 [15354273.001]
  • [Cites] Curr Opin Gastroenterol. 2003 Jul;19(4):366-70 [15703578.001]
  • [Cites] Nervenarzt. 2001 Feb;72(2):136-42 [11256148.001]
  • [Cites] Acta Neuropathol. 2000 Jun;99(6):709-14 [10867808.001]
  • [Cites] P R Health Sci J. 2005 Sep;24(3):191-5 [16329682.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):203-8 [10563424.001]
  • [Cites] Ann Intern Med. 1989 Oct 15;111(8):641-9 [2802419.001]
  • [Cites] Am J Gastroenterol. 1999 Nov;94(11):3248-53 [10566724.001]
  • [Cites] Neurology. 1986 Jul;36(7):1011-2 [3714049.001]
  • [Cites] Ann Neurol. 2000 May;47(5):682-3 [10805346.001]
  • [Cites] J Nephrol. 2005 Sep-Oct;18(5):521-8 [16299677.001]
  • [Cites] Brain Pathol. 2001 Oct;11(4):440-51 [11556690.001]
  • [Cites] J Neurol Sci. 2000 Dec 1;181(1-2):1-12 [11099705.001]
  • [Cites] J Neurol. 1979 Jan 5;220(4):259-68 [90135.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Jul;16(7):1225-32 [12144571.001]
  • [Cites] Invest New Drugs. 2005 Dec;23(6):523-32 [16267626.001]
  • [Cites] Ann Rheum Dis. 1980 Oct;39(5):457-61 [7436577.001]
  • [Cites] Pathol Res Pract. 1998;194(7):473-86 [9728364.001]
  • [Cites] Am J Clin Oncol. 2005 Aug;28(4):427-8 [16062089.001]
  • [Cites] Transplantation. 2003 Sep 27;76(6):930-7 [14508356.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1504-10 [12237919.001]
  • [Cites] Scand J Gastroenterol Suppl. 2002;(236):48-53 [12408504.001]
  • [Cites] Am J Epidemiol. 2005 Nov 15;162(10):965-74 [16192343.001]
  • [Cites] Gut. 2000 Oct;47(4):514-9 [10986211.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Aug;15(8):1101-8 [11472312.001]
  • [Cites] Herpes. 2004 Jun;11 Suppl 2:120A-127A [15319099.001]
  • [Cites] Ann Rheum Dis. 1988 Dec;47(12):988-92 [3207388.001]
  • [Cites] Neurology. 2001 Jan 23;56(2):257-60 [11160967.001]
  • [Cites] Am J Hematol. 2002 Mar;69(3):171-8 [11891803.001]
  • [Cites] Wien Klin Wochenschr. 2005 Mar;117(5-6):229-33 [15875764.001]
  • [Cites] Ann Rheum Dis. 1984 Apr;43(2):128-31 [6712287.001]
  • [Cites] Am J Med. 1985 Jan 21;78(1A):44-9 [3970040.001]
  • [Cites] Environ Mol Mutagen. 1999;34(2-3):131-9 [10529737.001]
  • [Cites] J Neurooncol. 2005 Aug;74(1):91-2 [16078114.001]
  • [Cites] Mod Pathol. 1999 Feb;12(2):200-17 [10071343.001]
  • [Cites] Arthritis Rheum. 1972 Mar-Apr;15(2):183-6 [4554891.001]
  • [Cites] Leuk Lymphoma. 1997 Dec;28(1-2):187-93 [9498719.001]
  • (PMID = 17375274.001).
  • [ISSN] 0028-2804
  • [Journal-full-title] Der Nervenarzt
  • [ISO-abbreviation] Nervenarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; MRK240IY2L / Azathioprine
  • [Number-of-references] 48
  •  go-up   go-down


62. Butturini A, Frappaz D: The challenges of high-dose chemotherapy in CNS tumors. Pediatr Blood Cancer; 2010 Apr;54(4):652-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The challenges of high-dose chemotherapy in CNS tumors.
  • High-dose, myeloablative chemotherapy with hematopoietic stem cell rescue is used in children and young adults with brain tumors for which conventional therapy is either excessively toxic (e.g., radiotherapy in infants) or ineffective.
  • We will consider the difficulties in analyzing published data and the challenges of designing effective clinical trials that test high-dose chemotherapy in patients with brain tumors.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Central Nervous System Neoplasms / drug therapy
  • [MeSH-minor] Child. Combined Modality Therapy. Hematopoietic Stem Cell Transplantation. Humans. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20146215.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 4
  •  go-up   go-down


63. Fliessbach K, Helmstaedter C, Urbach H, Althaus A, Pels H, Linnebank M, Juergens A, Glasmacher A, Schmidt-Wolf IG, Klockgether T, Schlegel U: Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology; 2005 Apr 12;64(7):1184-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study.
  • BACKGROUND: Combined radio- and chemotherapy for primary CNS lymphoma (PCNSL) is associated with a considerable risk of long-term neurotoxicity.
  • OBJECTIVE: To assess the impact of the tumor itself and its treatment with high-dose MTX-based chemotherapy on long-term cognition and QOL in patients with PCNSL.
  • CONCLUSION: In patients with primary CNS lymphoma (PCNSL) treated with a methotrexate (MTX)-based chemotherapy, no gross cognitive decline has to be expected as a long-term treatment effect.
  • Nevertheless, a substantial fraction of patients with PCNSL retain cognitive deficits as a residual symptom of the tumor.
  • [MeSH-major] Brain / drug effects. Brain Neoplasms / drug therapy. Cognition Disorders / chemically induced. Cognition Disorders / diagnosis. Lymphoma / drug therapy. Methotrexate / adverse effects
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / adverse effects. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nerve Fibers, Myelinated / drug effects. Nerve Fibers, Myelinated / pathology. Neuropsychological Tests. Prospective Studies. Psychomotor Performance / drug effects. Quality of Health Care. Time. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15824344.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


64. Burgetova A, Seidl Z, Vaneckova M, Jakoubkova M: Concurrent occurrence of multiple sclerosis and primary CNS lymphoma: a case report. Neuro Endocrinol Lett; 2008 Dec;29(6):867-70
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent occurrence of multiple sclerosis and primary CNS lymphoma: a case report.
  • Unexpectedly, this patient presented dramatical clinical deterioration and revealed clinical symptoms such as bradypsychia, cognitive symptoms, central vestibulare syndrome, spastic quadruparesis.
  • A histological examination confirmed primary CNS lymphoma (PCNSL).
  • [MeSH-major] Brain Neoplasms / complications. Lymphoma, B-Cell / complications. Multiple Sclerosis, Relapsing-Remitting / complications
  • [MeSH-minor] Adult. Central Nervous System Neoplasms / complications. Central Nervous System Neoplasms / pathology. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112415.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  •  go-up   go-down


65. Khatua S, Dhall G, O'Neil S, Jubran R, Villablanca JG, Marachelian A, Nastia A, Lavey R, Olch AJ, Gonzalez I, Gilles F, Nelson M, Panigrahy A, McComb G, Krieger M, Fan J, Sposto R, Finlay JL: Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation. Pediatr Blood Cancer; 2010 Jul 15;55(1):42-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation.
  • BACKGROUND: The purpose of this study was to evaluate a reduced irradiation dose strategy for newly diagnosed primary central nervous system (CNS) germinomas.
  • Initial tumor markers for beta-human chorionic gonadotrophin (HCGbeta) and alpha-fetoprotein (AFP) were evaluated in serum and lumbar cerebrospinal fluid (CSF).
  • RESULTS: Eighteen of 20 patients are without evidence of residual or recurrent tumor.
  • Both relapsing patients were subsequently determined to harbor malignant non-germinomatous germ cell tumor (NGGCT).
  • CONCLUSION: Chemotherapy followed by reduced dose whole ventricular and local boost irradiation appears to be effective in patients with localized pure CNS germinoma with evidence of preservation of neurocognitive function.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Central Nervous System Neoplasms / therapy. Germinoma / therapy. Neoplasms, Germ Cell and Embryonal / therapy
  • [MeSH-minor] Adolescent. Adult. Carboplatin / adverse effects. Carboplatin / therapeutic use. Child. Child, Preschool. Chorionic Gonadotropin, beta Subunit, Human / blood. Combined Modality Therapy. Dose-Response Relationship, Radiation. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Retrospective Studies. Young Adult. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20222020.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


66. Rodríguez D, Cheung MC, Housri N, Quinones-Hinojosa A, Camphausen K, Koniaris LG: Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005). J Surg Res; 2009 Oct;156(2):340-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005).
  • BACKGROUND: Determine the role of surgery and radiation therapy for patients with malignant CNS ependymomas.
  • Univariate analysis demonstrated that age, gender, ethnicity, primary tumor site, WHO grade and surgical resection were significant predictors of improved survival for ependymoma patients.
  • Multivariate analysis identified that a WHO grade III tumor, male gender, patient age, intracranial tumor locations and failure to undergo surgical resection were independent predictors of poorer outcomes.
  • For partially resected tumors, radiation therapy provides significant survival benefit.
  • [MeSH-major] Central Nervous System Neoplasms / radiotherapy. Central Nervous System Neoplasms / surgery. Ependymoma / radiotherapy. Ependymoma / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. SEER Program. Treatment Outcome. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577759.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Pestalozzi BC, Francis P, Quinaux E, Dolci S, Azambuja E, Gelber RD, Viale G, Balil A, Andersson M, Nordenskjöld B, Gnant M, Gutierrez J, Láng I, Crown JP, Piccart-Gebhart M, BIG 02-98 Collaborative Group: Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial. Ann Oncol; 2008 Nov;19(11):1837-41
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial.
  • BACKGROUND: Breast cancer central nervous system (CNS) metastases are an increasingly important problem because of high CNS relapse rates in patients treated with trastuzumab and/or taxanes.
  • After a median follow-up of 5 years, 403 patients had died and detailed information on CNS relapse was collected for these patients.
  • RESULTS: CNS relapse occurred in 4.0% of control patients and 3.7% of docetaxel-treated patients.
  • CNS relapse occurred in 27% of deceased patients in both treatment groups.
  • CNS relapse was usually accompanied by neurologic symptoms (90%), and 25% of patients with CNS relapse died without evidence of extra-CNS relapse.
  • Only 20% of patients survived 1 year from the diagnosis of CNS relapse.
  • Prognosis of CNS relapse was worse for patients with meningeal carcinomatosis when compared with brain metastases.
  • CONCLUSION: There is no evidence that adjuvant docetaxel treatment is associated with an increased frequency of CNS relapse.

  • Genetic Alliance. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2006 Jun;17(6):935-44 [16603601.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1133-44 [17675394.001]
  • [Cites] J Natl Cancer Inst. 2008 Jan 16;100(2):121-33 [18182617.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2349-51 [10829059.001]
  • [Cites] Ann Oncol. 2001 Mar;12(3):353-6 [11332148.001]
  • [Cites] Ann Oncol. 2005 Nov;16(11):1772-7 [16150805.001]
  • [Cites] Cancer. 2004 Oct 15;101(8):1760-6 [15386311.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):232-6 [8625097.001]
  • [Cites] Breast Cancer Res Treat. 2004 Dec;88(3):273-80 [15609130.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):44-55 [15630443.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Cancer. 2003 Jun 15;97(12):2972-7 [12784331.001]
  • (PMID = 18562328.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-73362
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2733076
  •  go-up   go-down


68. Chu LC, Eberhart CG, Grossman SA, Herman JG: Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer; 2006 Nov 15;119(10):2487-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic silencing of multiple genes in primary CNS lymphoma.
  • Primary central nervous system lymphoma (PCNSL) is an increasingly common tumor that has not been extensively examined for changes in promoter region methylation.
  • We examined 14 tumor suppressor genes in 25 cases of PCNSL using methylation-specific PCR.
  • Methylation of DAPK, p16(INK) (4a) or MGMT was found in 96% of the tumors, suggesting simple marker strategies to detect circulating methylated DNA in serum that might facilitate early tumor detection.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Epigenesis, Genetic. Gene Silencing. Genes, Tumor Suppressor. Lymphoma / genetics
  • [MeSH-minor] Adult. Aged. DNA Methylation. DNA, Neoplasm / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Promoter Regions, Genetic


69. Rani SB, Mahadevan A, Anilkumar SR, Raju TR, Shankar SK: Expression of nestin--a stem cell associated intermediate filament in human CNS tumours. Indian J Med Res; 2006 Sep;124(3):269-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of nestin--a stem cell associated intermediate filament in human CNS tumours.
  • Expression of this protein in various CNS tumour cells suggests the possibility of existence of tumour stem cell modulating the evolution.
  • [MeSH-major] Central Nervous System Neoplasms / metabolism. Glial Fibrillary Acidic Protein / metabolism. Intermediate Filament Proteins / metabolism. Nerve Tissue Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Fetus. Humans. Immunohistochemistry. Male. Microscopy, Confocal. Middle Aged. Nestin

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Indian J Med Res. 2006 Sep;124(3):229-30 [17085825.001]
  • (PMID = 17085830.001).
  • [ISSN] 0971-5916
  • [Journal-full-title] The Indian journal of medical research
  • [ISO-abbreviation] Indian J. Med. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


70. Ferreri AJ, Dell'Oro S, Foppoli M, Bernardi M, Brandes AA, Tosoni A, Montanari M, Balzarotti M, Spina M, Ilariucci F, Zaja F, Stelitano C, Bobbio F, Corazzelli G, Baldini L, Ponzoni M, Picozzi P, Caligaris Cappio F, Reni M: MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology; 2006 May 9;66(9):1435-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas.
  • The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Cranial Irradiation. Lymphoma, Non-Hodgkin / drug therapy. Radiotherapy, Adjuvant
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects. Female. Hematologic Diseases / chemically induced. Humans. Idarubicin / administration & dosage. Idarubicin / adverse effects. Life Tables. Male. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / mortality. Meningeal Neoplasms / radiotherapy. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Remission Induction. Stroke / etiology. Survival Analysis. Thiotepa / administration & dosage. Thiotepa / adverse effects

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16682682.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 905Z5W3GKH / Thiotepa; YL5FZ2Y5U1 / Methotrexate; ZRP63D75JW / Idarubicin; MATILDE regimen
  •  go-up   go-down


71. Seymour ZA, Panigrahy A, Finlay JL, Nelson MD Jr, Blüml S: Citrate in pediatric CNS tumors? AJNR Am J Neuroradiol; 2008 May;29(5):1006-11
Hazardous Substances Data Bank. CITRIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Citrate in pediatric CNS tumors?
  • BACKGROUND AND PURPOSE: In a subset of in vivo MR spectra acquired from pediatric brain tumors, we have observed an unassigned peak.
  • The goal of this study was to determine the molecule of origin, and the prevalence and concentration of this chemical in various pediatric brain tumors.
  • MATERIALS AND METHODS: Single-voxel point-resolved spectroscopy (PRESS) spectra from 85 patients with brain tumors and 469 control subjects were analyzed.
  • CONCLUSION: MR signal consistent with citrate was observed in pediatric brain tumors and in the developing brain of infants younger than 6 months.
  • [MeSH-major] Brain / metabolism. Brain Neoplasms / metabolism. Citric Acid / metabolism. Magnetic Resonance Spectroscopy / methods
  • [MeSH-minor] Adolescent. Adult. Biomarkers / metabolism. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18272551.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA97452-02
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 2968PHW8QP / Citric Acid
  •  go-up   go-down


72. Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, Issa S, Damon L, Prados M, McDermott M, O'Brien J, Haqq C, Shuman M: Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol; 2007 Apr 10;25(11):1350-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.
  • Systemic rituximab does not reduce the risk of CNS relapse or dissemination in patients with large cell lymphoma.
  • We therefore conducted a phase I dose-escalation study of intrathecal rituximab monotherapy in patients with recurrent CNS non-Hodgkin's lymphoma (NHL).
  • CONCLUSION: These results suggest that intrathecal rituximab (10 to 25 mg) is feasible and effective in NHL involving the CNS.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Central Nervous System Neoplasms / drug therapy. Eye Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Dose-Response Relationship, Drug. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Oct 1;25(28):4508-9; author reply 4509-11 [17906219.001]
  • (PMID = 17312328.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR-00079; United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / R01 CA101042-01
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


73. da Silva NS, Cappellano AM, Diez B, Cavalheiro S, Gardner S, Wisoff J, Kellie S, Parker R, Garvin J, Finlay J: Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study. Pediatr Blood Cancer; 2010 Mar;54(3):377-83
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study.
  • BACKGROUND: The treatment of central nervous system (CNS) germ cell tumors (GCT) remains controversial.
  • METHODS: Between January 2001 and December 2004 newly diagnosed patients with CNS GCT were treated with one of two risk-tailored chemotherapy regimens.
  • Twenty-five patients aged 4 months to 24.5 years were stratified: Regimen A consisted of 4-6 cycles of carboplatin/etoposide alternating with cyclophosphamide/etoposide for low risk (LR) localized germinoma with normal cerebrospinal fluid (CSF) and serum tumor markers.
  • Our results indicate that, at the present time, standard treatment for CNS GCT continues to include irradiation either alone or combined with chemotherapy for pure germinomas and with chemotherapy for those with MMGCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Neoplasms, Germ Cell and Embryonal / drug therapy
  • [MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Carboplatin / adverse effects. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Infant. Male. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 20063410.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


74. Galimi F, Summers RG, van Praag H, Verma IM, Gage FH: A role for bone marrow-derived cells in the vasculature of noninjured CNS. Blood; 2005 Mar 15;105(6):2400-2
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A role for bone marrow-derived cells in the vasculature of noninjured CNS.
  • Bone marrow-derived endothelial progenitor cells are thought to generate endothelial cells in many tissues, including myocardium, muscle, and certain tumors.
  • In the central nervous system (CNS), however, the possible role of bone marrow-derived angiocompetent cells remains unclear.
  • Using hematopoietic chimeras stably expressing green fluorescent protein (GFP) in bone marrow-derived tissues, we found large numbers of hematopoietic cells closely associated with vessels in the CNS.
  • Bone marrow-derived, vasculature-associated cells in the noninjured adult CNS are distinct from endothelial cells, but play an active role in vascular structures.
  • [MeSH-major] Bone Marrow Cells / physiology. Central Nervous System / physiology. Endothelial Cells / physiology. Neovascularization, Physiologic. Stem Cell Transplantation. Transplantation Chimera / physiology
  • [MeSH-minor] Animals. Mice. Mice, Transgenic. Microglia / cytology. Microglia / physiology. Monocytes / cytology. Monocytes / physiology. Muscle, Skeletal / blood supply. Muscle, Skeletal / cytology. Muscle, Skeletal / metabolism. Myocardium / cytology. Myocardium / metabolism. Neoplasms / blood supply. Neoplasms / metabolism. Neovascularization, Pathologic / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15572598.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


75. Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, Frickhofen N, Feuerhake F, Volk B, Finke J: High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol; 2006 Aug 20;24(24):3865-70
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
  • PURPOSE: To improve survival and reduce toxicity in primary CNS lymphoma (PCNSL) treatment, we conducted a multicenter phase II study with early high-dose chemotherapy (HDT) and autologous stem-cell transplantation (ASCT) followed by hyperfractionated whole-brain radiotherapy (WBRT) for newly diagnosed PCNSL patients younger than 65 years of age.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Hematopoietic Stem Cell Transplantation. Lymphoma / drug therapy. Lymphoma / radiotherapy
  • [MeSH-minor] Adult. Carmustine / administration & dosage. Chemotherapy, Adjuvant / adverse effects. Cranial Irradiation. Cytarabine / administration & dosage. Dose Fractionation. Drug Administration Schedule. Female. Germany. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Radiotherapy, Adjuvant / adverse effects. Thiotepa / administration & dosage. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16864853.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 905Z5W3GKH / Thiotepa; U68WG3173Y / Carmustine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


76. Kiewe P, Fischer L, Martus P, Thiel E, Korfel A: Meningeal dissemination in primary CNS lymphoma: diagnosis, treatment, and survival in a large monocenter cohort. Neuro Oncol; 2010 Apr;12(4):409-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningeal dissemination in primary CNS lymphoma: diagnosis, treatment, and survival in a large monocenter cohort.
  • The frequency of meningeal dissemination (MD) in primary CNS lymphoma (PCNSL), its prognostic impact, and optimal management have not been defined thus far.
  • [MeSH-major] Central Nervous System Neoplasms / mortality. Central Nervous System Neoplasms / pathology. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / pathology. Meningeal Neoplasms / mortality. Meningeal Neoplasms / secondary
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Neurol. 1995 Aug;38(2):202-9 [7654067.001]
  • [Cites] J Neurooncol. 2009 Feb;91(3):299-305 [18931887.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):733-9 [9477107.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]
  • [Cites] Am J Clin Pathol. 1998 Sep;110(3):341-6 [9728609.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3000-6 [9738568.001]
  • [Cites] Blood. 1999 Sep 1;94(5):1738-46 [10477699.001]
  • [Cites] Blood. 2005 Jan 15;105(2):496-502 [15358629.001]
  • [Cites] Br J Haematol. 2005 Jan;128(2):177-83 [15638851.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):445-9 [15653703.001]
  • [Cites] J Neurooncol. 2005 Apr;72(2):169-77 [15925998.001]
  • [Cites] Acta Oncol. 2005;44(7):728-34 [16227164.001]
  • [Cites] Haematologica. 2006 Mar;91(3):429-30 [16531273.001]
  • [Cites] J Neurol Sci. 2006 Aug 15;247(1):39-46 [16678210.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4570-4 [17008697.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5711-5 [17116938.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):237-9 [10563429.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):2077-86 [10595937.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):519-26 [10653867.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]
  • [Cites] Br J Neurosurg. 2000 Aug;14(4):313-5; discussion 316 [11045195.001]
  • [Cites] Diagn Cytopathol. 2000 Dec;23(6):369-74 [11074639.001]
  • [Cites] Neurology. 2002 Feb 12;58(3):390-6 [11839837.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4643-8 [12488408.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1044-9 [12637469.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2726-31 [12860951.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4483-8 [14597741.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4489-95 [14597744.001]
  • [Cites] Br J Haematol. 2004 Mar;124(6):762-8 [15009064.001]
  • [Cites] Neurology. 1979 Oct;29(10):1369-75 [573381.001]
  • [Cites] Blood. 1989 May 15;73(7):1942-50 [2713509.001]
  • [Cites] Ann Neurol. 1995 Jul;38(1):51-7 [7611725.001]
  • [Cites] Neurology. 2007 May 15;68(20):1674-9 [17502548.001]
  • [Cites] Cancer. 2008 Apr 15;112(8):1812-20 [18318432.001]
  • [Cites] Neurology. 2008 Sep 30;71(14):1102-8 [18824675.001]
  • [Cites] Br J Haematol. 1997 Oct;99(1):122-30 [9359512.001]
  • (PMID = 20308318.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2940610
  •  go-up   go-down


77. Yamanaka R, Shinbo Y, Sano M, Homma J, Tsuchiya N, Yajima N, Tamura T, Hondoh H, Takahashi H, Morii K, Onda K, Tanaka R: Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen. Leuk Lymphoma; 2007 Jun;48(6):1119-26
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.
  • We report the efficacy of salvage therapy with a modified ProMACE-MOPP combined with radiation in patients with primary central nervous system lymphoma (PCNSL).
  • Nine patients with CNS relapse were retreated with additional cycles of the ProMACE-MOPP hybrid regimen with a 90% objective response rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Lymphoma / drug therapy. Lymphoma / radiotherapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / analogs & derivatives. Doxorubicin / therapeutic use. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Male. Mechlorethamine / adverse effects. Mechlorethamine / therapeutic use. Methotrexate / adverse effects. Methotrexate / therapeutic use. Middle Aged. Neurotoxicity Syndromes / drug therapy. Neurotoxicity Syndromes / radiotherapy. Prednisone / adverse effects. Prednisone / therapeutic use. Procarbazine / adverse effects. Procarbazine / therapeutic use. Retrospective Studies. Survival Analysis. Vincristine / adverse effects. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577775.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; D58G680W0G / pirarubicin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ProMACE-MOPP protocol
  •  go-up   go-down


78. Montesinos-Rongen M, Schmitz R, Brunn A, Gesk S, Richter J, Hong K, Wiestler OD, Siebert R, Küppers R, Deckert M: Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma. Acta Neuropathol; 2010 Oct;120(4):529-35
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma.
  • Primary CNS lymphoma (PCNSL), the intracerebral subgroup of diffuse large B cell lymphoma (DLBCL), shows evidence for aberrant activation of the nuclear factor (NF)-kappaB pathway.
  • [MeSH-major] CARD Signaling Adaptor Proteins / genetics. Central Nervous System Neoplasms / enzymology. Guanylate Cyclase / genetics. Lymphoma / enzymology. Mutation / genetics. NF-kappa B / metabolism. Signal Transduction / genetics
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Male. Middle Aged. Proteins / genetics. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20544211.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CARD Signaling Adaptor Proteins; 0 / NF-kappa B; 0 / Proteins; 0 / TNIP3 protein, human; EC 4.6.1.2 / CARD11 protein, human; EC 4.6.1.2 / Guanylate Cyclase
  •  go-up   go-down


79. Manninger SP, Muldoon LL, Nesbit G, Murillo T, Jacobs PM, Neuwelt EA: An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions. AJNR Am J Neuroradiol; 2005 Oct;26(9):2290-300
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions.
  • BACKGROUND AND PURPOSE: Iron oxide-based contrast agents have been investigated as more specific MR imaging agents for central nervous system (CNS) inflammation.
  • Ferumoxtran-10 is a virus-size nanoparticle, taken up by reactive cells, that allows visualization of the phagocytic components of CNS lesions.
  • Ferumoxtran-10 was compared with standard gadolinium-enhanced MR images in this exploratory trial to assess its potential in evaluation of CNS lesions with inflammatory aspects, including lymphoma, multiple sclerosis (MS), acute disseminated encephalomyelitis (ADEM), and vascular lesions.
  • RESULTS: In 5 cases, (one ADEM, 2 stroke, one cavernous venous vascular malformation, one primary central nervous lymphoma) the ferumoxtran-10 scan showed higher signal intensity, larger area of enhancement, or new enhancing areas compared with gadolinium.
  • CONCLUSION: Ferumoxtran-10 showed different enhancement patterns in a variety of CNS lesions with inflammatory components in comparison to gadolinium.
  • The impact of timing and therapy need further evaluation to better assess ferumoxtran-10 in addition to gadolinium as contrast agents for use in diagnosis and monitoring therapy in patients with CNS inflammatory lesions.
  • [MeSH-major] Blood-Brain Barrier / physiopathology. Central Nervous System Diseases / diagnosis. Contrast Media. Iron. Magnetic Resonance Imaging. Oxides. Phagocytes / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / pathology. Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Cerebrovascular Disorders / diagnosis. Cerebrovascular Disorders / pathology. Demyelinating Diseases / diagnosis. Demyelinating Diseases / pathology. Dextrans. Female. Ferrosoferric Oxide. Gadolinium DTPA. Humans. Inflammation. Magnetite Nanoparticles. Male. Middle Aged. Nanostructures

  • MedlinePlus Health Information. consumer health - Iron.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16219835.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5 M01 RR00034; United States / NINDS NIH HHS / NS / NS034608
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Magnetite Nanoparticles; 0 / Oxides; 0 / ferumoxtran-10; 84F6U3J2R6 / gadodiamide; E1UOL152H7 / Iron; K2I13DR72L / Gadolinium DTPA; K3R6ZDH4DU / Dextrans; XM0M87F357 / Ferrosoferric Oxide
  •  go-up   go-down


80. Cady FM, O'Neill BP, Law ME, Decker PA, Kurtz DM, Giannini C, Porter AB, Kurtin PJ, Johnston PB, Dogan A, Remstein ED: Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol; 2008 Oct 10;26(29):4814-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course.
  • PURPOSE: Primary CNS lymphoma (PCNSL) is an aggressive lymphoma but clinically validated biologic markers that can predict natural history to tailor treatment according to risk are lacking.
  • Several genetic changes including BCL6 rearrangements and deletion of 6q22, containing the putative tumor suppressor gene PTPRK, are potential risk predictors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2006 Aug;65(8):776-82 [16896311.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):737-41 [12591717.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):447-51 [12640061.001]
  • [Cites] Am J Surg Pathol. 2003 Apr;27(4):487-93 [12657933.001]
  • [Cites] Virchows Arch. 2003 Aug;443(2):164-9 [12802586.001]
  • [Cites] Cerebrovasc Dis. 2004;17(2-3):224-7 [14707426.001]
  • [Cites] Cell. 2004 Jun 11;117(6):699-711 [15186772.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):159-66 [15215171.001]
  • [Cites] Blood. 1994 Apr 1;83(7):1757-9 [8142643.001]
  • [Cites] Blood. 1994 May 1;83(9):2423-7 [8167331.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Nov;7(11):833-46 [17057753.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1546-53 [17122510.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5711-5 [17116938.001]
  • [Cites] Blood. 1995 May 15;85(10):2877-84 [7742550.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):615-20 [9635710.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jun;25(2):123-33 [10337996.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1507-13 [15735126.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2233-9 [15800313.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3179-82 [16101124.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5718-27 [16009945.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3183-90 [16046532.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2466-72 [16240449.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1652-60 [16327438.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1281-8 [16525183.001]
  • [Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2332-43 [17625604.001]
  • [Cites] Blood. 2008 Jan 1;111(1):292-301 [17720884.001]
  • [Cites] Leukemia. 2008 Feb;22(2):400-5 [17989719.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1268-72 [17989713.001]
  • [Cites] Nat Rev Immunol. 2005 Jan;5(1):43-57 [15630428.001]
  • [Cites] Am J Pathol. 1999 Nov;155(5):1445-51 [10550299.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1386-92 [10555007.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):261-6 [10659013.001]
  • [Cites] Brain Pathol. 2000 Jan;10(1):73-84 [10668897.001]
  • [Cites] Neurosurgery. 2000 Aug;47(2):454-6; discussion 456-7 [10942021.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Mar;125(2):147-50 [11369058.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Br J Haematol. 2002 May;117(2):322-32 [11972514.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Oct;61(10):926-33 [12387458.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Lancet. 2003 Jan 25;361(9354):323-31 [12559880.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1383-97 [8055462.001]
  • (PMID = 18645192.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA15083; United States / NCI NIH HHS / CA / P50 CA108961
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins
  • [Other-IDs] NLM/ PMC2653136
  •  go-up   go-down


81. Doolittle ND, Abrey LE, Shenkier TN, Tali S, Bromberg JE, Neuwelt EA, Soussain C, Jahnke K, Johnston P, Illerhaus G, Schiff D, Batchelor T, Montoto S, Kraemer DF, Zucca E: Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood; 2008 Feb 1;111(3):1085-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report.
  • Isolated central nervous system (CNS) relapse involving the brain parenchyma is a rare complication of systemic non-Hodgkin lymphoma.
  • After complete response to initial non-Hodgkin lymphoma treatment, patients with isolated CNS relapse with the brain parenchyma as initial relapse site were eligible.
  • Patients with isolated CNS relapse involving only the cerebrospinal fluid were not eligible.
  • Brain relapse was identified by neuroimaging in all patients; in 54 (48%), diagnostic brain tumor specimen was obtained.
  • Our results suggest systemic methotrexate is the optimal treatment for isolated CNS relapse involving the brain parenchyma.
  • [MeSH-major] Brain Neoplasms / secondary. Central Nervous System Neoplasms / secondary. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cerebral Hemorrhage. Female. Humans. Male. Middle Aged. Recurrence


82. Maza S, Kiewe P, Munz DL, Korfel A, Hamm B, Jahnke K, Thiel E: First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma. Neuro Oncol; 2009 Aug;11(4):423-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.
  • Most patients with primary CNS lymphoma (PCNSL) relapse after primary therapy.
  • Anti-CD20 immunotherapy has expanded treatment options in systemic B-cell lymphoma; however, its use is limited by reconstitution of the blood-brain barrier after tumor shrinkage.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Central Nervous System Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radioimmunotherapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / radiotherapy. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Male. Middle Aged. Prognosis. Prospective Studies. Remission Induction. Survival Rate. Tissue Distribution. Yttrium Radioisotopes / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1999 Jul;43(3):249-57 [10563431.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2453-63 [12011122.001]
  • [Cites] Blood. 2003 Jan 15;101(2):466-8 [12393404.001]
  • [Cites] Eur J Cancer. 1991;27(11):1356-61 [1835848.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] Eur J Haematol. 2005 Apr;74(4):348-52 [15777348.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2528-34 [17932895.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1710-1 [15972281.001]
  • [Cites] J Neurooncol. 2006 Mar;77(1):53-8 [16283435.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Nov;7(3):236-8 [17229341.001]
  • [Cites] J Neurooncol. 2007 Jul;83(3):291-3 [17245621.001]
  • [Cites] Leuk Lymphoma. 2007 Sep;48(9):1712-20 [17786706.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • (PMID = 19060176.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  • [Other-IDs] NLM/ PMC2743222
  •  go-up   go-down


83. Badruddoja MA, Keir ST, King I, Zeidner J, Vredenburgh JJ, Muhlbaier LH, Bigner DD, Friedman HS: Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice. Neuro Oncol; 2007 Jul;9(3):240-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice.
  • The current study was designed to assess the activity of VNP40101M administered at a dose of 18 mg/kg daily for five days against a panel of human adult and pediatric CNS tumors growing subcutaneously or intracranially in athymic nude mice.
  • The results demonstrated statistically significant (p < 0.05) growth delays of 15.0, 8.3, 51.0, 60+, 60+, and 60+ days in subcutaneous xenografts derived from childhood glioblastoma multiforme (D-456 MG), childhood ependymoma (D-528 EP and D-612 EP), childhood medulloblastoma (D-425 MED), and adult malignant glioma (D-245 MG and D-54 MG), respectively, with corresponding tumor regressions in 10 of 10, 4 of 10, 8 of 10, 9 of 10, 9 of 10, and 10 of 10 treated mice, respectively.
  • Additional experiments conducted against subcutaneous D-245 MG xenografts by using reduced doses of 13.5 or 9.0 mg/kg daily for five days demonstrated tumor growth delays of 82.2 and 53.5 days, with corresponding tumor regressions in 8 of 9 and 9 of 10 treated mice, respectively (all values, p < 0.001), with one toxic death.
  • These findings suggest that VNP40101M is active in the treatment of a wide range of human central nervous system tumors and warrants translation to the clinic.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1994;34(2):171-4 [8194169.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72 [2164681.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2853-7 [7796412.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2933-6 [9230204.001]
  • [Cites] Invest New Drugs. 2005 Mar;23(2):123-35 [15744588.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Biochem Pharmacol. 2000 Feb 1;59(3):283-91 [10609557.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3033-8 [11306484.001]
  • [Cites] Int J Toxicol. 2002 Jan-Feb;21(1):23-38 [11936896.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Apr;53(4):288-95 [14685775.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2908-17 [15131024.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Neurosurgery. 1979 Apr;4(4):308-14 [450229.001]
  • [Cites] Cancer Res. 1988 Aug 1;48(15):4189-95 [3390813.001]
  • [Cites] J Neurooncol. 1994;20(2):111-20 [7807189.001]
  • (PMID = 17522334.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P50 NS020023; United States / NINDS NIH HHS / NS / 5P50-NS20023-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydrazines; 0 / Prodrugs; 0 / Sulfonamides; 14J2G0U3NQ / laromustine
  • [Other-IDs] NLM/ PMC1907418
  •  go-up   go-down


84. Salzburg J, Burkhardt B, Zimmermann M, Wachowski O, Woessmann W, Oschlies I, Klapper W, Wacker HH, Ludwig WD, Niggli F, Mann G, Gadner H, Riehm H, Schrappe M, Reiter A: Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol; 2007 Sep 1;25(25):3915-22
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
  • PURPOSE: We analyzed the prevalence, clinical pattern, and prognostic impact of CNS involvement in a large cohort of children and adolescents diagnosed with non-Hodgkin's lymphoma (NHL), with special attention to differences according to NHL subtype.
  • RESULTS: CNS involvement was diagnosed in 141 (5.9%) of 2,381 patients and was associated with an advanced stage of NHL.
  • The percentage of CNS-positive patients was 8.8% for Burkitt's lymphoma/Burkitt's leukemia (BL/B-ALL), 5.4% for precursor B-lymphoblastic lymphoma (pB-LBL), 3.3% for anaplastic large-cell lymphoma, 3.2% for T-cell-LBL, 2.6% for diffuse large B-cell lymphoma, and 0% for primary mediastinal large B-cell NHL (P < .001).
  • Most CNS-positive patients with pB-LBL, T-LBL, or BL/B-ALL had meningeal disease.
  • For the 112 CNS-positive patients, pEFS was 64% +/- 5%, compared with 86% +/- 1% for the 1,927 CNS-negative patients (P < .001).
  • Although CNS disease had no impact on pEFS for advanced-stage T-LBL patients, CNS-positive patients with BL/B-ALL had a worse average outcome than CNS-negative patients with stage IV BL/B-ALL (60% +/- 5% v 81% +/- 3%; P < .001).
  • In multivariate analysis, CNS disease was the strongest predictor for relapse in BL/B-ALL patients with advanced-stage disease.
  • CONCLUSION: Six percent of childhood/adolescent NHL patients were CNS positive.
  • However, the prevalence, pattern, and prognostic impact of CNS involvement differed among NHL subtypes.
  • [MeSH-major] Brain Neoplasms / epidemiology. Head and Neck Neoplasms / epidemiology. Lymphoma, Non-Hodgkin / classification. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Epidural Neoplasms / epidemiology. Epidural Neoplasms / therapy. Female. Germany / epidemiology. Humans. Infant. Infant, Newborn. Male. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prevalence. Prognosis. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17761975.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


85. Wernicke AG, Sherr DL, Schwartz TH, Pannullo SC, Stieg PE, Boockvar JA, Moliterno JA, Ivanidze J, Trichter S, Sabbas AM, Parashar B, Nori D: The role of dose escalation with intracavitary brachytherapy in the treatment of localized CNS malignancies: outcomes and toxicities of a prospective study. Brachytherapy; 2010 Jan-Mar;9(1):91-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of dose escalation with intracavitary brachytherapy in the treatment of localized CNS malignancies: outcomes and toxicities of a prospective study.
  • PURPOSE: This single-institution prospective study was designed to investigate the feasibility and safety of dose escalation with GliaSite (Proxima Therapeutics Inc., Alpharetta, GA) brachytherapy for the treatment of patients with newly diagnosed and recurrent central nervous system (CNS) tumors after neurosurgical resection.
  • METHODS AND MATERIALS: Ten adult consecutive patients with recurrent and newly diagnosed CNS malignancies underwent GliaSite brachytherapy after maximally safe neurosurgical resection between 2004 and 2007.
  • A commercial 3-D planning system was used for a detailed analysis of dosimetry.
  • CONCLUSIONS: Our data indicate that treatment with GliaSite balloon brachytherapy is feasible and safe, while rendering acceptable local control and minimal acute and long-term toxicities for newly diagnosed and recurrent CNS malignancies.
  • [MeSH-major] Brachytherapy / adverse effects. Brain Injuries / diagnosis. Brain Injuries / etiology. Brain Neoplasms / radiotherapy. Radiation Injuries / diagnosis. Radiation Injuries / etiology
  • [MeSH-minor] Adult. Aged. Dose Fractionation. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
  • (PMID = 19850535.001).
  • [ISSN] 1873-1449
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Hendrickson KC, Rimar J: Patterns of hospital resource utilization of children with leukemia and CNS tumors: a comparison of children who survive and those who die within 3 years of diagnosis. Nurs Econ; 2009 Jan-Feb;27(1):35-44
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of hospital resource utilization of children with leukemia and CNS tumors: a comparison of children who survive and those who die within 3 years of diagnosis.
  • The two childhood cancers most commonly requiring hospitalization are leukemia and tumors of the central nervous system (CNS tumors).
  • [MeSH-major] Central Nervous System Neoplasms / economics. Health Care Costs. Hospitalization / statistics & numerical data. Leukemia / economics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Intensive Care Units, Pediatric / utilization. Length of Stay. Male. New England. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19331311.001).
  • [ISSN] 0746-1739
  • [Journal-full-title] Nursing economic$
  • [ISO-abbreviation] Nurs Econ
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Ellenberg L, Liu Q, Gioia G, Yasui Y, Packer RJ, Mertens A, Donaldson SS, Stovall M, Kadan-Lottick N, Armstrong G, Robison LL, Zeltzer LK: Neurocognitive status in long-term survivors of childhood CNS malignancies: a report from the Childhood Cancer Survivor Study. Neuropsychology; 2009 Nov;23(6):705-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurocognitive status in long-term survivors of childhood CNS malignancies: a report from the Childhood Cancer Survivor Study.
  • To assess neurocognitive functioning in adult survivors of childhood Central Nervous System (CNS) malignancy, a large group of CNS malignancy survivors were compared to survivors of non-CNS malignancy and siblings without cancer on a self-report instrument (CCSS-NCQ) assessing four factors, Task Efficiency, Emotional Regulation, Organization and Memory.
  • Additional multiple linear regressions were used to assess the contribution of demographic, illness, and treatment variables to reported neurocognitive functioning in CNS malignancy survivors and the relationship of reported neurocognitive functioning to socioeconomic indicators.
  • Survivors of CNS malignancy reported significantly greater neurocognitive impairment on all CCSS-NCQ factors than non-CNS cancer survivors or siblings (p < .01).
  • Within the CNS malignancy group, medical complications (hearing deficits, paralysis and cerebrovascular incidents) resulted in a greater likelihood of reported deficits on all CCSS-NCQ factors.
  • CNS malignancy survivors with more impaired CCSS-NCQ scores demonstrated significantly lower educational attainment (p < .01), less household income (p < .001), less full time employment (p < .001), and fewer marriages (p < .001).
  • Survivors of childhood CNS malignancy were found to be at significant risk for neurocognitive impairment that continues to adulthood and is correlated with lower socioeconomic achievement.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5198-204 [16051961.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):137-45 [10477017.001]
  • [Cites] Arch Clin Neuropsychol. 2006 Oct;21(7):721-32 [16979868.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5283-90 [17114662.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3649-56 [17704415.001]
  • [Cites] J Pediatr Psychol. 2007 Oct;32(9):1029-37 [17426043.001]
  • [Cites] J Pediatr. 2008 Jan;152(1):101-5 [18154909.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):435-46 [18268128.001]
  • [Cites] Neuropsychology. 2008 Mar;22(2):159-68 [18331158.001]
  • [Cites] J Consult Clin Psychol. 2008 Jun;76(3):367-78 [18540731.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2188-97 [18792068.001]
  • [Cites] Ann Neurol. 1999 Dec;46(6):834-41 [10589535.001]
  • [Cites] Pediatr Neurol. 2000 Feb;22(2):106-12 [10738915.001]
  • [Cites] Brain. 2000 May;123 ( Pt 5):1041-50 [10775548.001]
  • [Cites] Brain. 2000 May;123 ( Pt 5):1051-61 [10775549.001]
  • [Cites] Neuropsychology. 2000 Apr;14(2):189-200 [10791859.001]
  • [Cites] Dev Med Child Neurol. 2000 Nov;42(11):741-5 [11104345.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2302-8 [11304784.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):174-83 [11465398.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3470-6 [11481352.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2709-19 [11745207.001]
  • [Cites] Neuropsychology. 2002 Jan;16(1):15-27 [11853353.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] Med Pediatr Oncol. 2003 Jan;40(1):26-34 [12426683.001]
  • [Cites] Cancer. 2003 May 15;97(10):2512-9 [12733151.001]
  • [Cites] Curr Probl Cancer. 2003 Jul-Aug;27(4):177-97 [12855950.001]
  • [Cites] Brain. 2003 Sep;126(Pt 9):1998-2008 [12876140.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3255-61 [12947060.001]
  • [Cites] Neuropsychology. 2003 Oct;17(4):548-55 [14599268.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):706-13 [14966095.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):999-1006 [15020603.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):399-408 [15231246.001]
  • [Cites] Mol Interv. 2004 Oct;4(5):273-84 [15471910.001]
  • [Cites] Biometrics. 1986 Mar;42(1):121-30 [3719049.001]
  • [Cites] Neurosurgery. 1987 Nov;21(5):638-44 [3696394.001]
  • [Cites] J Clin Oncol. 1991 Apr;9(4):592-9 [2066756.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(1):13-6 [1727109.001]
  • [Cites] Med Pediatr Oncol. 1992;20(3):181-91 [1574027.001]
  • [Cites] Int J Dev Neurosci. 1994 Jun;12(4):327-34 [7976487.001]
  • [Cites] Br J Cancer. 1996 Mar;73(6):825-30 [8611389.001]
  • [Cites] Brain. 1998 Apr;121 ( Pt 4):561-79 [9577385.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1723-8 [9586884.001]
  • [Cites] Neuropsychology. 2006 Jan;20(1):105-12 [16460226.001]
  • (PMID = 19899829.001).
  • [ISSN] 1931-1559
  • [Journal-full-title] Neuropsychology
  • [ISO-abbreviation] Neuropsychology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA055727-06A1; United States / NCI NIH HHS / CA / U24 CA055727; United States / NCI NIH HHS / CA / U24 CA055727-06A1; United States / NCI NIH HHS / CA / U24 CA55727
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS157997; NLM/ PMC2796110
  •  go-up   go-down


88. Ustun C, Reid-Nicholson M, Nayak-Kapoor A, Jones-Crawford J, McDonald K, Jillella AP, Ramalingam P: Plasmablastic lymphoma: CNS involvement, coexistence of other malignancies, possible viral etiology, and dismal outcome. Ann Hematol; 2009 Apr;88(4):351-8
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma: CNS involvement, coexistence of other malignancies, possible viral etiology, and dismal outcome.
  • Central nervous system (CNS) involvement was identified in four out of five (80%) patients.
  • Our experience in patients with PBL indicates that CNS involvement is more common than reported in the literature.
  • [MeSH-major] Central Nervous System Neoplasms / etiology. Lymphoma, Non-Hodgkin / etiology. Neoplasms, Plasma Cell / etiology
  • [MeSH-minor] Adult. Female. HIV / isolation & purification. Herpesvirus 8, Human / isolation & purification. Humans. Male. Middle Aged. Neoplasms, Second Primary / classification. Retrospective Studies. Survival Rate

  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18787825.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


89. Ligon KL, Fancy SP, Franklin RJ, Rowitch DH: Olig gene function in CNS development and disease. Glia; 2006 Jul;54(1):1-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olig gene function in CNS development and disease.
  • Olig1 and Olig2 encode basic helix-loop-helix (bHLH) transcription factors that are expressed in both the developing and mature vertebrate central nervous system.
  • Recent studies, however, reveal that in the fetal dorsal spinal cord and neural progenitor cells of the adult brain, Olig expression continues to mark, and may regulate, the formation of oligodendroglia.
  • Studies of Olig expression in human brain tumors and repair of demyelinating lesions suggest the possibility of additional functions in a variety of neurological diseases.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / metabolism. Cell Differentiation / genetics. Central Nervous System / embryology. Gene Expression Regulation, Developmental / genetics. Nerve Tissue Proteins / metabolism. Oligodendroglia / metabolism. Stem Cells / metabolism
  • [MeSH-minor] Animals. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Brain Neoplasms / therapy. Cell Lineage / genetics. Demyelinating Diseases / genetics. Demyelinating Diseases / metabolism. Demyelinating Diseases / therapy. Humans

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16652341.001).
  • [ISSN] 0894-1491
  • [Journal-full-title] Glia
  • [ISO-abbreviation] Glia
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Nerve Tissue Proteins; 0 / OLIG1 protein, human
  • [Number-of-references] 106
  •  go-up   go-down


90. Fischer L, Thiel E, Klasen HA, Birkmann J, Jahnke K, Martus P, Korfel A: Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol; 2006 Jul;17(7):1141-5
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective trial on topotecan salvage therapy in primary CNS lymphoma.
  • BACKGROUND: Standard salvage therapy has not been established for recurrent primary central nervous system lymphoma (PCNSL).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16603598.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan
  •  go-up   go-down


91. Mohile NA, Deangelis LM, Abrey LE: Utility of brain FDG-PET in primary CNS lymphoma. Clin Adv Hematol Oncol; 2008 Nov;6(11):818-20, 840
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of brain FDG-PET in primary CNS lymphoma.
  • However, its utility in primary central nervous system lymphoma (PCNSL) is unclear.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Lymphoma / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain / pathology. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194366.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


92. Varikatt W, Dexter M, Mahajan H, Murali R, Ng T: Usefulness of smears in intra-operative diagnosis of newly described entities of CNS. Neuropathology; 2009 Dec;29(6):641-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of smears in intra-operative diagnosis of newly described entities of CNS.
  • The recent edition of World Health Organisation (WHO) Classification of Tumours of the Central Nervous System has incorporated a substantial number of important changes.
  • [MeSH-major] Brain Neoplasms / pathology. Glioma / pathology
  • [MeSH-minor] Adolescent. Female. Frozen Sections. Humans. Intraoperative Period. Pineal Gland / pathology. Pineal Gland / surgery. World Health Organization. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563508.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 24
  •  go-up   go-down


93. Ng S, Butzkueven H, Kalnins R, Rowe C: Prolonged interval between sentinel pseudotumoral demyelination and development of primary CNS lymphoma. J Clin Neurosci; 2007 Nov;14(11):1126-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged interval between sentinel pseudotumoral demyelination and development of primary CNS lymphoma.
  • Primary central nervous system lymphoma (PCNSL) can be associated with preceding demyelinating pseudotumoral brain lesions.
  • [MeSH-major] Brain Neoplasms / complications. Demyelinating Diseases / complications. Lymphoma, B-Cell / complications. Lymphoma, Non-Hodgkin / complications. Pseudotumor Cerebri / complications
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Positron-Emission Tomography. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Neurosci. 2008 Sep;15(9):1069-70; author reply 1071 [18617406.001]
  • (PMID = 17890092.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


94. Cabanillas M, Aneiros A, Monteagudo B, Santos-García D, Suárez-Amor O, Ramírez-Santos A: Epidermal nevus syndrome associated with polyostotic fibrous dysplasia, CNS lipoma, and aplasia cutis. Dermatol Online J; 2009;15(10):7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal nevus syndrome associated with polyostotic fibrous dysplasia, CNS lipoma, and aplasia cutis.
  • Epidermal nevus syndrome is a rare congenital sporadic neurocutaneous disorder characterized by an epidermal nevus and various developmental abnormalities of the skin, eyes, nervous, cardiovascular and urogenital systems.
  • We describe a patient with an extensive epidermal nevus associated with various organ abnormalities, particularly polyostotic fibrous dysplasia, central nervous system lipoma, and aplasia cutis.
  • [MeSH-major] Ectodermal Dysplasia / complications. Fibrous Dysplasia, Polyostotic / complications. Lipoma / complications. Neoplasms, Multiple Primary. Nevus / complications. Skin Neoplasms / complications. Spinal Cord Neoplasms / complications
  • [MeSH-minor] Adult. Humans. Male


95. Lotze C, Schüler F, Krüger WH, Hirt C, Kirsch M, Vogelgesang S, Schmidt CA, Dölken G: Combined immunoradiotherapy induces long-term remission of CNS relapse of peripheral, diffuse, large-cell lymphoma after allogeneic stem cell transplantation: case study. Neuro Oncol; 2005 Oct;7(4):508-10
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined immunoradiotherapy induces long-term remission of CNS relapse of peripheral, diffuse, large-cell lymphoma after allogeneic stem cell transplantation: case study.
  • Relapse of peripheral non-Hodgkin's lymphoma (NHL) in the central nervous system commonly has a poor prognosis.
  • On day +83 after transplantation a CNS relapse of the lymphoma occurred.
  • [MeSH-major] Antibodies / therapeutic use. Brain Neoplasms / radiotherapy. Graft vs Leukemia Effect / physiology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Antigens, CD20 / immunology. Humans. Male. Neoplasm Recurrence, Local / immunology. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Cancer Res. 2001;82:133-85 [11447762.001]
  • [Cites] Bone Marrow Transplant. 2003 Oct;32(8):843-6 [14520432.001]
  • [Cites] Blood. 2004 Jan 15;103(2):725-31 [12947008.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2208-16 [10498590.001]
  • [Cites] Bone Marrow Transplant. 1997 Sep;20(6):503-6 [9313885.001]
  • [Cites] Blood. 1998 Feb 15;91(4):1178-84 [9454747.001]
  • [Cites] Leuk Lymphoma. 1999 Jun;34(1-2):185-90 [10350348.001]
  • [Cites] Blood. 1990 Dec 15;76(12):2462-5 [2265242.001]
  • (PMID = 16212815.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD20
  • [Other-IDs] NLM/ PMC1871735
  •  go-up   go-down


96. Ruppert AM, Beau-Faller M, Neuville A, Guerin E, Voegeli AC, Mennecier B, Legrain M, Molard A, Jeung MY, Gaub MP, Oudet P, Quoix E: EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. Eur Respir J; 2009 Feb;33(2):436-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
  • However, after an initial response, most patients will recur, particularly within the central nervous system.
  • Persistent cerebral tyrosine kinase inhibitor sensitivity should be considered in patients presenting with an early central nervous system relapse after stopping epidermal growth factor receptor tyrosine kinase inhibitor, even with a T790M-resistant mutation in noncerebral metastases.
  • Questions remain concerning the selection of sub-clones during epidermal growth factor receptor tyrosine kinase inhibitor therapy, which could differ according to metastatic sites, especially in the central nervous system.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Central Nervous System Neoplasms / secondary. Central Nervous System Neoplasms / therapy. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Erlotinib Hydrochloride. Humans. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Male. Neoplasm Metastasis. Quinazolines / administration & dosage. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19181917.001).
  • [ISSN] 1399-3003
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


97. Fouladi M, Stewart CF, Blaney SM, Onar-Thomas A, Schaiquevich P, Packer RJ, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ: Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J Clin Oncol; 2010 Sep 20;28(27):4221-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
  • PURPOSE: To estimate the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetic properties of lapatinib, a selective epidermal growth factor receptor (EGFR) and ERBB2 inhibitor, in children with refractory or recurrent CNS malignancies.
  • Expression of the four ERBB receptors and downstream signaling elements in tumor tissue was evaluated by immunohistochemistry.
  • Frequent, high-level expression of activated (phosphorylated) EGFR and ERBB2 receptors and downstream signal intermediates were observed in tumors, particularly in ependymomas that displayed prolonged stable disease on lapatinib therapy.
  • CONCLUSION: Lapatinib is well tolerated in children with recurrent CNS malignancies, with rash, diarrhea, and fatigue identified as DLTs.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Central Nervous System Neoplasms / drug therapy. Protein Kinase Inhibitors / administration & dosage. Quinazolines / administration & dosage
  • [MeSH-minor] Administration, Oral. Adolescent. Child. Child, Preschool. Diarrhea / chemically induced. Exanthema / chemically induced. Fatigue / chemically induced. Female. Humans. Infant. Male. Maximum Tolerated Dose. Phosphorylation. Receptor, Epidermal Growth Factor / analysis. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, ErbB-2 / analysis. Receptor, ErbB-2 / antagonists & inhibitors. Steroids / therapeutic use. Treatment Outcome. United States. Young Adult

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2000 Jul 3;19(13):3159-67 [10880430.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 Jan;65(2):353-61 [19499221.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Oncogene. 2002 Sep 12;21(41):6255-63 [12214266.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3054-64 [12374672.001]
  • [Cites] Mol Cancer Ther. 2001 Dec;1(2):85-94 [12467226.001]
  • [Cites] Lancet Oncol. 2003 Jul;4(7):397-406 [12850190.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3620-4 [14506149.001]
  • [Cites] Mol Cell. 2003 Sep;12(3):541-52 [14527402.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):984-93 [14970185.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):317-28 [15093539.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 18;319(1):1-11 [15158434.001]
  • [Cites] Oncologist. 2004;9 Suppl 3:10-5 [15163842.001]
  • [Cites] Mol Cell Biol. 1989 Mar;9(3):1165-72 [2566907.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4838-48 [9354447.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):786-92 [15728811.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5305-13 [15955900.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 2;831(1-2):169-75 [16364699.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1630-9 [16452222.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16 [16829981.001]
  • [Cites] Trends Cell Biol. 2006 Dec;16(12):649-56 [17085050.001]
  • [Cites] N Engl J Med. 2006 Dec 28;355(26):2733-43 [17192538.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3137-43 [17634493.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3397-8 [17635950.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3753-8 [17704424.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):1993-9 [18421051.001]
  • [Cites] Semin Oncol. 2008 Jun;35(3):286-97 [18544443.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4484-90 [18628463.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4921-7 [18794549.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1452-9 [19228746.001]
  • [Cites] J Biopharm Stat. 2009;19(3):437-55 [19384687.001]
  • [Cites] Clin Pharmacol Ther. 2000 Oct;68(4):356-66 [11061575.001]
  • (PMID = 20713864.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA129541; United States / NCI NIH HHS / CA / U01 CA081457; United States / NCI NIH HHS / CA / U01CA81457
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / Steroids; 0VUA21238F / lapatinib; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2953974
  •  go-up   go-down


98. Maule M, Scélo G, Pastore G, Brennan P, Hemminki K, Pukkala E, Weiderpass E, Olsen JH, Tracey E, McBride ML, Brewster DH, Pompe-Kirn V, Tonita JM, Kliewer EV, Chia KS, Jonasson JG, Martos C, Magnani C, Boffetta P: Risk of second malignant neoplasms after childhood central nervous system malignant tumours: an international study. Eur J Cancer; 2008 Apr;44(6):830-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of second malignant neoplasms after childhood central nervous system malignant tumours: an international study.
  • PURPOSE: The aim of this study was to assess the risk of second malignant neoplasms (SMNs) other than central nervous system (CNS) neoplasms after childhood CNS cancer in an international multicentre study.
  • METHODS: Individual data on cases of CNS cancer in children (0-14 years) and on subsequent SMNs were obtained from 13 population-based cancer registries contributing data for different time periods in 1943-2000.
  • RESULTS: We observed 43 SMNs in 8431 CNS cancer survivors.
  • The SIRs were highest in the first 10 years after CNS cancer diagnosis.
  • The cumulative incidence of non-CNS SMNs was 3.30% (0.95-5.65%) within 45 years after a CNS cancer diagnosis.
  • CONCLUSION: This population-based study indicates that about one every 180 survivors of a childhood CNS cancer will develop a non-CNS SMN within the following 15 years.
  • The excess is higher after glioma and embryonal malignant tumour than after another CNS tumour.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Epidemiologic Methods. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Risk

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18329873.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R03 CA101442-02
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


99. Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F, International Extranodal Lymphoma Study Group (IELSG): High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet; 2009 Oct 31;374(9700):1512-20
University of Turin Instituional Repository AperTO. Full Text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
  • BACKGROUND: Chemotherapy with high-dose methotrexate is the conventional approach to treat primary CNS lymphomas, but superiority of polychemotherapy compared with high-dose methotrexate alone is unproven.
  • We assessed the effect of adding high-dose cytarabine to methotrexate in patients with newly diagnosed primary CNS lymphoma.
  • 79 patients with non-Hodgkin lymphoma exclusively localised into the CNS, cranial nerves, or eyes, aged 18-75 years, and with Eastern Cooperative Oncology Group performance status of 3 or lower and measurable disease were centrally randomly assigned by computer to receive four courses of either methotrexate 3.5 g/m(2) on day 1 (n=40) or methotrexate 3.5 g/m(2) on day 1 plus cytarabine 2 g/m(2) twice a day on days 2-3 (n=39).
  • INTERPRETATION: In patients aged 75 years and younger with primary CNS lymphoma, the addition of high-dose cytarabine to high-dose methotrexate provides improved outcome with acceptable toxicity compared with high-dose methotrexate alone.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Cytarabine / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Methotrexate / therapeutic use
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Cranial Irradiation / methods. Drug Administration Schedule. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Logistic Models. Middle Aged. Proportional Hazards Models. Remission Induction. Treatment Outcome


100. Sonoda Y, Matsumoto K, Kakuto Y, Nishino Y, Kumabe T, Tominaga T, Katakura R: Primary CNS lymphoma treated with combined intra-arterial ACNU and radiotherapy. Acta Neurochir (Wien); 2007 Nov;149(11):1183-9; discussion 1189
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary CNS lymphoma treated with combined intra-arterial ACNU and radiotherapy.
  • OBJECT: To assess whether nimustine (ACNU), a drug that can cross the blood brain barrier, combined with radiotherapy, improved the survival of patients with primary central nervous system lymphoma (PCNSL).
  • By multivariate analysis, age (<60 vs. > or =60 years) was the only statistically significant prognostic factor; the WBRT dose, sex, and number of tumors were not significant prognostic factors in this study.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Cranial Irradiation. Infusions, Intra-Arterial. Lymphoma, B-Cell / drug therapy. Lymphoma, T-Cell / drug therapy. Nimustine / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17712511.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0S726V972K / Nimustine
  •  go-up   go-down






Advertisement